1. Introduction
===============

The topic of pharmaceuticals in the environment (PIE) has gained a lot of attention in environmental discussions. Active pharmaceutical ingredients (APIs) are suspected of causing unintended adverse effects in environmental compartments, based on their intended property of high biological activity. For human APIs, which are excreted into wastewater, this primarily means concern for the sewage treatment plants (STPs) or surface waters. Such concerns have been fuelled by ubiquitous detections of APIs in STP effluents and surface waters since the 1970s, in concentrations in the ng/L to µg/L range. It is mostly older APIs that are regularly monitored and detected. While for the registration of new APIs an environmental risk assessment (ERA) has been requested in the European Union since the early 1990s \[[@B1-antibiotics-02-00115]\], this was not the case beforehand, meaning that exactly for these older APIs there often is a lack of environmental fate and toxicity data.

The old antibiotic trimethoprim (TMP) was first put on the market by F. Hoffmann-La Roche Ltd (Roche) in the 1960s in combination with sulfamethoxazole (SMX) under the brand name of Bactrim^®^. TMP has been regularly detected in the environment. Like all antibiotics, TMP has come under suspicion for the potential of selecting for, maintaining or increasing antibiotic resistance in environmental bacteria. The first in-depth aquatic ERA for TMP is presented here. It is based on both predicted and measured environmental concentrations (PECs and MECs, respectively) and on published and new chronic ecotoxicity data. Some of the latter were specifically commissioned in order to produce a solid effects assessment for TMP. Acute ecotoxicity data are integrated as well. In view of sufficient data available, this ERA was supplemented with a probabilistic comparison of percent-ranked MECs and chronic effects species sensitivity distributions in addition to the standard deterministic procedures.

2. Results and Discussion
=========================

2.1. Trimethoprim Pharmacological Data
--------------------------------------

### 2.1.1. TMP Mode of Action

The diaminopyrimidine TMP (2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine; CAS Number 738-70-5) \[[@B2-antibiotics-02-00115]\] is a bacteriostatic API that interferes with the bacterial dihydrofolate reductase enzyme, inhibiting the synthesis of tetrahydrofolic acid \[[@B2-antibiotics-02-00115]\]. Bacteria are unable to take up folic acid from the environment, including their infection host in case of pathogenic species, and are dependent on their own *de novo* synthesis. Inhibition of dihydrofolate reductase starves the bacteria of nucleotides necessary for DNA replication. TMP is generally used in combination with sulfonamide antibiotics (mainly SMX), which interfere with another step of bacterial folate synthesis pathway; in combination, TMP and SMX act synergistically.

### 2.1.2. TMP Adsorption, Metabolism and Excretion

TMP is rapidly absorbed after oral administration and widely distributed around the body to tissues and fluids. Serum therapeutic concentrations range from 1.5--2.5 mg/L up to 9 mg/L \[[@B3-antibiotics-02-00115]\]. Metabolic reactions include oxidation of the methylene group to a hydroxymethyl group, *N*-oxidation, *O*-de-methylation and hydroxylation in phase-1 metabolism as well as conjugation with glucuronic acid or sulfate in phase 2. Around 10%--20% of a dose is metabolized. The metabolites are excreted in the urine as conjugates, but the greater part of the dose is excreted as unchanged drug. Urinary excretion is *p*H-dependent and is increased in acidic urine. About 40%--75% of a dose is excreted in 24 h, up to 60% being in the form of unchanged drug, with about 4% each as the 3\'-hydroxymethyl and 4\'-hydroxymethyl metabolites and 2% as the N1-oxide. Less than 4% is eliminated in the faeces. The plasma half-life ranges from 8 to 17 h with an average of 11 h \[[@B2-antibiotics-02-00115],[@B3-antibiotics-02-00115]\]. The World Health Organization defined daily dose of TMP is 400 mg \[[@B4-antibiotics-02-00115]\]. This value will later be used for the first PEC derivation.

### 2.1.3. TMP Toxicity

TMP is not particularly toxic to humans and mammals by oral administration in the short or longer term, however, it can be irritant and sensitizing \[[@B2-antibiotics-02-00115]\]. It was mutagenic in a bacterial test system and at high doses it can be teratogenic and embryotoxic through its mode of action, folate antagonism \[[@B2-antibiotics-02-00115]\], as folic acid is required for normal development. However, due to these mutagenic and reprotoxic properties, TMP is classified by default as T for toxic for a persistence, bioaccumulation and toxicity (PBT) assessment.

2.2. TMP Environmental Fate and Concentrations
----------------------------------------------

The basic data for the environmental fate and effects of TMP are listed in tables in the Appendix of this publication, starting on Page 136, for better readability of the text. A discussion of the most important, selected values from these tables is presented in the following sections.

### 2.2.1. Physico-Chemical Data for TMP

Physico-chemical data for TMP are listed in the Appendix in [Table A1](#antibiotics-02-00115-t001){ref-type="table"}, Page 136 *ff* \[[@B2-antibiotics-02-00115],[@B3-antibiotics-02-00115],[@B5-antibiotics-02-00115],[@B6-antibiotics-02-00115],[@B7-antibiotics-02-00115],[@B8-antibiotics-02-00115],[@B9-antibiotics-02-00115],[@B10-antibiotics-02-00115],[@B11-antibiotics-02-00115],[@B12-antibiotics-02-00115],[@B13-antibiotics-02-00115],[@B14-antibiotics-02-00115],[@B15-antibiotics-02-00115],[@B16-antibiotics-02-00115],[@B17-antibiotics-02-00115],[@B18-antibiotics-02-00115],[@B19-antibiotics-02-00115],[@B20-antibiotics-02-00115],[@B21-antibiotics-02-00115],[@B22-antibiotics-02-00115],[@B23-antibiotics-02-00115],[@B24-antibiotics-02-00115],[@B25-antibiotics-02-00115],[@B26-antibiotics-02-00115],[@B27-antibiotics-02-00115]\]. TMP is an organic base with a reasonably high water solubility of \~300 mg/L and a first base dissociation constant *p*K~a~ around the neutral *p*H point \[[@B2-antibiotics-02-00115]\]. There are no hydrolysable bonds. The melting point is around 200 °C \[[@B2-antibiotics-02-00115]\], vapor pressure is low at \~1.32 × 10^--6^ Pa \[[@B5-antibiotics-02-00115]\], hence the Henry's Law Constant is low as well and the substance will not volatilize from water. In addition, with a first base *p*K~a~ around 7 \[[@B2-antibiotics-02-00115],[@B3-antibiotics-02-00115],[@B9-antibiotics-02-00115]\], TMP is at least partly dissociated in most environmental waters, *i.e.*, it will be more hydrophilic and will volatilize even less. With an *n*-octanol/water partition coefficient logKow between 0.64 and 1.115 \[[@B2-antibiotics-02-00115],[@B12-antibiotics-02-00115]\] TMP is not particularly lipophilic. Therefore, neither strong adsorption to organic substrates nor bioaccumulation would be expected. In confirmation, moderate to low adsorption constants to organic carbon (OC), activated sludge (AS) and soil have been published \[[@B13-antibiotics-02-00115],[@B14-antibiotics-02-00115],[@B15-antibiotics-02-00115],[@B16-antibiotics-02-00115],[@B17-antibiotics-02-00115],[@B18-antibiotics-02-00115],[@B19-antibiotics-02-00115],[@B20-antibiotics-02-00115],[@B21-antibiotics-02-00115],[@B22-antibiotics-02-00115],[@B23-antibiotics-02-00115],[@B24-antibiotics-02-00115],[@B25-antibiotics-02-00115],[@B26-antibiotics-02-00115],[@B27-antibiotics-02-00115]\], although Lin & Gan \[[@B16-antibiotics-02-00115]\] noted strong adsorption in one soil beside moderate adsorption in others. Specifically, sorption to AS in sewage treatment plants (STPs) has been independently described as 'negligible' \[[@B25-antibiotics-02-00115],[@B26-antibiotics-02-00115],[@B27-antibiotics-02-00115]\]. However, sorption should still be kept in mind as Trapp *et al.* \[[@B28-antibiotics-02-00115]\] have shown using physicochemical activity-based environmental fate modeling that as a weak base, TMP is non-dissociated and thus more prone to sorption or bioaccumulation at a higher environmental *p*H of 9 than at *p*H 6 where TMP is mostly dissociated. In general, based on this low to moderate sorption, most TMP is expected to remain predominantly in the aqueous phase, meaning that little is removed to sludge in STPs, the exposure of soil by landspreading of digested surplus sludge is low, mobility in soils is high and little will partition from surface waters to sediment.

### 2.2.2. Biodegradation, Environmental Fate and Bioaccumulation Data for TMP

The available literature data for TMP for biodegradation, removal in STPs, environmental fate and derived half-lives as well as bioaccumulation are collated in [Table A2](#antibiotics-02-00115-t002){ref-type="table"}, [Table A3](#antibiotics-02-00115-t003){ref-type="table"}, [Table A4](#antibiotics-02-00115-t004){ref-type="table"}, [Table A5](#antibiotics-02-00115-t005){ref-type="table"} at the end (Page 138 *ff*).

#### 2.2.2.1. Biodegradability of TMP ([Table A2](#antibiotics-02-00115-t002){ref-type="table"}) \[[@B18-antibiotics-02-00115],[@B19-antibiotics-02-00115],[@B21-antibiotics-02-00115],[@B25-antibiotics-02-00115],[@B26-antibiotics-02-00115],[@B29-antibiotics-02-00115],[@B30-antibiotics-02-00115],[@B31-antibiotics-02-00115],[@B32-antibiotics-02-00115],[@B33-antibiotics-02-00115],[@B34-antibiotics-02-00115],[@B35-antibiotics-02-00115]\]

TMP is recalcitrant to biodegradation in standard ready and inherent tests \[[@B18-antibiotics-02-00115],[@B21-antibiotics-02-00115],[@B29-antibiotics-02-00115],[@B31-antibiotics-02-00115]\] and also in a standard STP model test at low concentration \[[@B32-antibiotics-02-00115]\]. This first impression may be misleading, however, as on one hand, significant cometabolic degradation was observed in a closed bottle test with sodium acetate in the toxicity control \[[@B29-antibiotics-02-00115]\]. Moreover, good removal (\>50%) was seen in those tests performed with aerobic AS with a long sludge retention time (SRT), *i.e.*, a high sludge age \[[@B21-antibiotics-02-00115],[@B25-antibiotics-02-00115],[@B33-antibiotics-02-00115],[@B34-antibiotics-02-00115],[@B35-antibiotics-02-00115]\]. Indeed, as consistently shown by Göbel *et al.* \[[@B19-antibiotics-02-00115],[@B26-antibiotics-02-00115]\], Perez *et al.* \[[@B34-antibiotics-02-00115]\] and Schröder *et al.* \[[@B35-antibiotics-02-00115]\], who compared the removal in different steps of STPs, low removal was found in inocula with a short SRT, e.g., from primary sludge or young AS, but high removal was noted for inocula with a high SRT, *i.e.*, nitrifying AS and sand filters. Similarly, rapid primary degradation of TMP was also shown by Löffler & Ternes \[[@B36-antibiotics-02-00115]\] for natural sediments and by Schmidt *et al.* \[[@B37-antibiotics-02-00115]\] during river bank filtration. In addition, Bundschuh *et al.* \[[@B30-antibiotics-02-00115]\] determined that TMP is even rapidly degraded in a ready-type system, exposing fallen leaves in natural water to low concentrations of TMP, where they determined \~80% degradation in 7 days. A similar difference may also exist for anaerobic degradation as Gartiser *et al.* \[[@B21-antibiotics-02-00115]\] recorded no significant methane production in a standard ISO 11734 anaerobic degradation test, while other investigations with surplus sludge from an anaerobic digestor \[[@B19-antibiotics-02-00115]\], with manure and anaerobic bacteria \[[@B38-antibiotics-02-00115]\] or in pig slurry \[[@B39-antibiotics-02-00115]\] found high and rapid removal. In soil \[[@B13-antibiotics-02-00115],[@B40-antibiotics-02-00115]\] and seawater \[[@B41-antibiotics-02-00115]\], however, biodegradation seems to be slow with correspondingly long half-lives of around or more than 100 days.

#### 2.2.2.2. Removal of TMP during Sewage Treatment ([Table A3](#antibiotics-02-00115-t003){ref-type="table"}) \[[@B19-antibiotics-02-00115],[@B23-antibiotics-02-00115],[@B25-antibiotics-02-00115],[@B36-antibiotics-02-00115],[@B37-antibiotics-02-00115],[@B38-antibiotics-02-00115],[@B42-antibiotics-02-00115],[@B43-antibiotics-02-00115],[@B44-antibiotics-02-00115],[@B45-antibiotics-02-00115],[@B46-antibiotics-02-00115],[@B47-antibiotics-02-00115],[@B48-antibiotics-02-00115],[@B49-antibiotics-02-00115],[@B50-antibiotics-02-00115],[@B51-antibiotics-02-00115],[@B52-antibiotics-02-00115],[@B53-antibiotics-02-00115],[@B54-antibiotics-02-00115],[@B55-antibiotics-02-00115],[@B56-antibiotics-02-00115],[@B57-antibiotics-02-00115],[@B58-antibiotics-02-00115],[@B59-antibiotics-02-00115],[@B60-antibiotics-02-00115],[@B61-antibiotics-02-00115],[@B62-antibiotics-02-00115],[@B63-antibiotics-02-00115],[@B64-antibiotics-02-00115],[@B65-antibiotics-02-00115],[@B66-antibiotics-02-00115],[@B67-antibiotics-02-00115],[@B68-antibiotics-02-00115],[@B69-antibiotics-02-00115],[@B70-antibiotics-02-00115],[@B71-antibiotics-02-00115],[@B72-antibiotics-02-00115],[@B73-antibiotics-02-00115],[@B74-antibiotics-02-00115]\]

The above differences, mainly relating to SRT respectively nitrifying conditions, are probably responsible for the inordinately high range of removal noted for many different STPs in Europe, North America and the Far East. These include negative removal, which may signify cleavage of glucuronide or sulfate conjugates \[[@B75-antibiotics-02-00115]\], and range up to nearly 100% \[[@B19-antibiotics-02-00115],[@B23-antibiotics-02-00115],[@B48-antibiotics-02-00115],[@B52-antibiotics-02-00115],[@B53-antibiotics-02-00115],[@B54-antibiotics-02-00115],[@B55-antibiotics-02-00115],[@B56-antibiotics-02-00115],[@B57-antibiotics-02-00115],[@B58-antibiotics-02-00115],[@B59-antibiotics-02-00115],[@B60-antibiotics-02-00115],[@B61-antibiotics-02-00115],[@B62-antibiotics-02-00115],[@B63-antibiotics-02-00115]\]. Some of the negative removal rates, like the extreme value of −550% described by Lindberg *et al.* \[[@B45-antibiotics-02-00115]\] for one STP in Sweden, are highly improbable, seeing as 60%--80% of ingested TMP is excreted as the parent and only 20%--40% as metabolites and conjugates \[[@B2-antibiotics-02-00115],[@B3-antibiotics-02-00115]\]. Therefore, conjugate cleavage of 550% is quite impossible, but either sampling, synchronization or analytical problems are suspected. In conclusion, for TMP in STPs there is but minor removal during inadequate primary and secondary treatment \[[@B19-antibiotics-02-00115],[@B34-antibiotics-02-00115]\], but nitrifying sludge is able to biodegrade TMP \[[@B25-antibiotics-02-00115],[@B34-antibiotics-02-00115]\], suggesting an important role for both aerobic conditions \[[@B76-antibiotics-02-00115]\] and in particular for long SRTs in secondary treatment \[[@B55-antibiotics-02-00115],[@B62-antibiotics-02-00115]\]. Similarly, anaerobic degradation may range from low \[[@B21-antibiotics-02-00115]\] to rather high \[[@B19-antibiotics-02-00115],[@B38-antibiotics-02-00115],[@B39-antibiotics-02-00115]\].

For later PEC refinement, the recorded removal rates for full-scale working STPs were collated from 26 references \[[@B19-antibiotics-02-00115],[@B23-antibiotics-02-00115],[@B25-antibiotics-02-00115],[@B42-antibiotics-02-00115],[@B43-antibiotics-02-00115],[@B44-antibiotics-02-00115],[@B45-antibiotics-02-00115],[@B46-antibiotics-02-00115],[@B47-antibiotics-02-00115],[@B48-antibiotics-02-00115],[@B49-antibiotics-02-00115],[@B50-antibiotics-02-00115],[@B51-antibiotics-02-00115],[@B52-antibiotics-02-00115],[@B53-antibiotics-02-00115],[@B54-antibiotics-02-00115],[@B55-antibiotics-02-00115],[@B56-antibiotics-02-00115],[@B57-antibiotics-02-00115],[@B58-antibiotics-02-00115],[@B59-antibiotics-02-00115],[@B60-antibiotics-02-00115],[@B61-antibiotics-02-00115],[@B62-antibiotics-02-00115],[@B63-antibiotics-02-00115],[@B64-antibiotics-02-00115]\] listed in [Table A3](#antibiotics-02-00115-t003){ref-type="table"} (with the exception of the above extreme value from \[[@B45-antibiotics-02-00115]\]). The 107 remaining recorded removal rates, representing at least 63 STPs, ranged from −128% \[[@B48-antibiotics-02-00115]\] up to \>99% \[[@B63-antibiotics-02-00115]\]. The average removal is 25.0% and the median removal 30.0% ([Figure 1](#antibiotics-02-00115-f001){ref-type="fig"}). These removal values are in agreement with the data by Fick *et al.* \[[@B60-antibiotics-02-00115]\] who determined TMP to fall into an average removal range between 10% and 49% in their Swedish investigation in the year 2010.

It is to be noted that all these empirically determined degradation rates depend on several circumstances, from time-corrected sampling of influents and effluents, to types and functional quality of the sewage works to the analytics themselves. While for the latter in most publications the analytical methods and recovery rates and ranges are described in detail, exact measured values are presented all the same, mostly without explicitly pointing out the uncertainty contained. This was recently shown by a group from Cleveland, Ohio sewage treatment works \[[@B77-antibiotics-02-00115]\] who used two different contract labs to evaluate both intralaboratory and interlaboratory variability. They found discrepancies in TMP quantification of 40% in the same influent and of 168%--180% for the same effluents. This finding calls for caution in regarding all the measured concentrations of TMP (and other substances) as representing a true value; they could in fact be lower or higher.

![Distribution of 107 published degradation/removal rates of Trimethoprim (TMP) in 63 sewage treatment plants (STPs) worldwide.](antibiotics-02-00115-g001){#antibiotics-02-00115-f001}

#### 2.2.2.3. Environmental Fate of TMP ([Table A4](#antibiotics-02-00115-t004){ref-type="table"}) \[[@B13-antibiotics-02-00115],[@B15-antibiotics-02-00115],[@B16-antibiotics-02-00115],[@B19-antibiotics-02-00115],[@B21-antibiotics-02-00115],[@B36-antibiotics-02-00115],[@B37-antibiotics-02-00115],[@B38-antibiotics-02-00115],[@B39-antibiotics-02-00115],[@B40-antibiotics-02-00115],[@B41-antibiotics-02-00115],[@B72-antibiotics-02-00115],[@B73-antibiotics-02-00115],[@B78-antibiotics-02-00115]\]

Hydrolysis \[[@B65-antibiotics-02-00115],[@B66-antibiotics-02-00115]\] and aquatic photodegradation in fresh and seawater \[[@B68-antibiotics-02-00115],[@B71-antibiotics-02-00115]\] are not significant for TMP, except where both hydrogen peroxide and scavengers are present at the same time as UV irradiation \[[@B66-antibiotics-02-00115],[@B70-antibiotics-02-00115],[@B71-antibiotics-02-00115],[@B72-antibiotics-02-00115]\]. Michael *et al.* \[[@B66-antibiotics-02-00115]\] and Wu *et al.* \[[@B72-antibiotics-02-00115]\] have recently confirmed that TMP degrades only slowly under natural solar illumination, approximately 10% in 500 min in demineralized water \[[@B66-antibiotics-02-00115]\], respectively up to \~2% in 72 h in natural water \[[@B72-antibiotics-02-00115]\]. However, it degrades much faster by hydrolysis in the aluminum-foil-wrapped dark control (up to \~15% in 72 h at *p*H 4 and 7), due to the temperature increase in the dark control \[[@B72-antibiotics-02-00115]\]. While dissolved organic matter, which can act as a scavenger, is common in natural waters, peroxides may be less so; moreover, in most instances the superficial temperature will not rise massively, due to water movement. Hence, only slow photodegradation is predicted for TMP in temperate zones and it is not expected to play a major role in the environmental fate of TMP.

Total environmental half-lives (t½) of TMP have been derived for some compartments. In an experimental microcosm, Lam *et al.* \[[@B65-antibiotics-02-00115]\] analytically determined a t½ of 5.7 ± 0.1 days; this short time may reflect the earlier findings of Bundschuh *et al.* \[[@B30-antibiotics-02-00115]\] in their miniature fallen-leaf/natural-water system. Extrapolated, *i.e.*, estimated environmental half-lives for TMP are available for freshwater with \>42 days \[[@B67-antibiotics-02-00115]\] and 20--100 days \[[@B73-antibiotics-02-00115]\]. Boxall *et al.* \[[@B67-antibiotics-02-00115]\] also estimated a freshwater sediment t½ of \>60--100 days, while Hektoen *et al.* \[[@B74-antibiotics-02-00115]\] predicted a marine sediment t½ of 75--100 days. Once more there seems to be a wide range of half-lives for TMP, from the measured 5.7 ± 0.1 days \[[@B65-antibiotics-02-00115]\] up to an estimated 100 days. This may again reflect nitrifying *vs.* non-nitrifying conditions, but mainly it does attest to a high uncertainty.

However, the half-lives are important as the EU Technical Guidance Document for Risk Assessment (TGD) \[[@B79-antibiotics-02-00115]\] classifies substances for persistence in function of their environmental half-life. Thereby, compounds are classified persistent (P) in freshwater if the aquatic half-life is \>40 days and very persistent (vP) if it is \>60 days; both P and vP in seawater if the marine half-life is \>60 days; P if the freshwater sediment half-life is \>120 days and vP if it is \>180 days; P and vP if the freshwater or marine sediment half-life is \>180 days \[[@B79-antibiotics-02-00115]\]. Based on one experimental half-life of 5.7 days in a microcosm \[[@B65-antibiotics-02-00115]\], TMP is not P, but it may well be P or even vP in freshwater if the extra­polated half-lives of \>42 days \[[@B67-antibiotics-02-00115]\] respectively 20--100 days \[[@B73-antibiotics-02-00115]\] are correct.

#### 2.2.2.4. Bioaccumulation Data for TMP ([Table A5](#antibiotics-02-00115-t005){ref-type="table"}) \[[@B9-antibiotics-02-00115],[@B28-antibiotics-02-00115],[@B47-antibiotics-02-00115],[@B67-antibiotics-02-00115],[@B80-antibiotics-02-00115],[@B81-antibiotics-02-00115],[@B82-antibiotics-02-00115],[@B83-antibiotics-02-00115],[@B84-antibiotics-02-00115]\]

Data on bioaccumulation for TMP are scarce or indirect. The lipophilicity data for TMP range from a logKow of 0.64 to 1.15 \[[@B2-antibiotics-02-00115],[@B6-antibiotics-02-00115],[@B11-antibiotics-02-00115],[@B12-antibiotics-02-00115]\], which argues against bioaccumulation. In an early experimental study, Bergsjø & Søgnen \[[@B9-antibiotics-02-00115]\] exposed trout to a high TMP concentration of 75 mg/L in fresh and saltwater, but only for a short time of 84 h, which might not suffice for rigorous bioaccumulation assessment. They found a maximum bioconcentration factor (BCF; concentration in fish ÷ concentration in medium) of \~0.32 in marine fish liver and \~0.16 in freshwater fish liver, but from some of the graphs given the internal concentration seems to be still on the rise. However, Bergsjø *et al.* had dosed rainbow trout orally with radio-labeled TMP earlier \[[@B83-antibiotics-02-00115]\] at a dose of roughly 0.02 mg TMP/g fish at 7 or 15 °C. Following the radio-label by autoradiography they noted a slow (maximum disintegrations per minute, DPM, around 48 h at 7 °C) to more rapid (max. DPM around 12--24 h at 15 °C) uptake, followed by a decrease that was rapid in muscle at 15 °C but slower in liver at 7 °C. Still, the maximum body concentration from a single dose reached at 48 h and declining thereafter does not speak for significant bioaccumulation. More recently, Fang *et al.* \[[@B81-antibiotics-02-00115]\] dosed Japanese bass *(Lateolabrax japonicus)* once daily with 125 mg sulfamethazine and 25 mg TMP over five days. They derived the minimum holding period, unstated in the abstract but presumably until the analytes were below the limit of detection, from analysis in muscle, blood, liver and kidney as 26 days at 22 °C water temperature and 30 days at 16 °C. While no further information is given in the available abstract, a minimum 90% depuration time of 30 days at 16 °C does not seem inordinately long, suggesting reasonably rapid depuration and thereby relatively low bioaccumulation. Using multi-compartment, physico-chemical-activity-based modeling, Trapp *et al.* \[[@B28-antibiotics-02-00115]\] showed that, contrary to expectation, TMP accumulates less in biota at *p*H 9 than at *p*H 6, due to increased relative partitioning to the sediment at *p*H 9 where TMP is mostly non-ionized. Conversely, according to Trapp and colleagues, at *p*H 6 TMP partitions more to biota than to sediment, but based on their data the worst-case water-biota BCF would still be \<100 (approximate value from [Figure 1](#antibiotics-02-00115-f001){ref-type="fig"} in Trapp *et al.*) \[[@B28-antibiotics-02-00115]\]. This is indirectly supported by the reports of Ramirez *et al.* \[[@B82-antibiotics-02-00115]\], who sampled common local fish from five wastewater-influenced streams in the eastern and southern USA as well as in one pristine control river, and Fick *et al.* \[[@B60-antibiotics-02-00115]\], who did a comparable sampling in Swedish rivers and associated fish. Both groups never detected TMP in any of their fish samples. Fick and colleagues analyzed both surface water and biota samples at the same places; based on their range of surface water TMP concentrations, from 6.8 to 210 ng/L with no non-detects, and the fish concentration consistently below their LOQ of 0.1 µg/kg \[[@B60-antibiotics-02-00115]\], the TMP BCF would be predicted to be \<16 in the worst case. The regulatory limit for aquatic bioaccumulation is a BCF of 2000 for bioaccumulative (B) or of 5000 for very bioaccumulative (vB) according to the EU TGD \[[@B79-antibiotics-02-00115]\]. Based on this mainly circumstantial evidence, TMP does not qualify as B.

For uptake and bioaccumulation from spiked soil to plants over full growth duration for lettuce (103 days) and carrots (152 days), Boxall *et al.* \[[@B40-antibiotics-02-00115]\] determined soil-based uptake factors of 0.06 for lettuce and 0.08 for carrots and soil-porewater-based uptake factors of 0.68 respectively 0.86 over the whole duration. Last, in a hydroponic exposure of two different sorts of cabbage plants, with 232.5 µg TMP/L in the nutrient solution over 51 days, Herklotz *et al.* \[[@B83-antibiotics-02-00115]\] found a maximum wet-weight BCF of 0.3074. Even though for soil uptake in plants lower limits may apply for a B classification than for animals in water \[[@B85-antibiotics-02-00115]\], with a BCF clearly \<1 on chronic exposure there is no suspicion of bioaccumulation. Recently, Sabourin *et al.* \[[@B84-antibiotics-02-00115]\] compared concentrations of pharmaceuticals and other substances in vegetables (sweet maize, carrot, tomato, potato) grown on soil fertilized with dried municipal sewage sludge or on non-amended control soil. Results for TMP are equivocal, as TMP was detected at comparable levels in tomatoes from one (0.432 ng TMP/g dry weight) of three amended soils and also from control soil (0.387 ng TMP/g dry weight), but was not detected in any other vegetable. The authors state that, by their own criterion that detections must be made in all three amended soils per vegetable, the results for all analytes including TMP are not significant. Hence, overall, there is no evidence for bioaccumulation of TMP.

2.3. TMP Environmental Concentrations
-------------------------------------

### 2.3.1. PECs and Use Data for Europe

The EMA 2006 Guideline for ERA of human pharmaceuticals \[[@B86-antibiotics-02-00115]\] derives the initial, crude surface water PEC for APIs with a simple formula, multiplying the maximum daily dose with a default penetration factor in the population of 0.01 and dividing by a default 200 L sewage per person and day and a default surface water dilution factor of 10, without factoring in any human metabolism or STP removal. For TMP, with a daily dose of 400 mg \[[@B4-antibiotics-02-00115]\], this results in a crude surface water PEC of 2 µg/L. However, this initial PEC may be refined through incorporating actual use, either through published epidemiological data resulting in a lower penetration factor or through actual use figures.

IMS Health is a company that collates sales figures for APIs, hence total TMP sales (*i.e.*, pharmacies plus hospitals wherever available) were retrieved from the IMS Health database \[[@B87-antibiotics-02-00115]\] for the years 1995--2003 for the following European countries: Austria, Belgium, France, Germany, Greece, Italy, The Netherlands, Portugal, Spain, Sweden, Switzerland and the United Kingdom, making up in 2003 a total of 370 million inhabitants \[[@B88-antibiotics-02-00115]\]. Two results appear from this collation, first, the overall use declined from 55,578 kg in 1995 to 43,079 kg in 2003; such a decline was also noted by ter Laak *et al.* in a 2010 RIWA report on temporal and spatial trends of pharmaceuticals in the River Rhine \[[@B89-antibiotics-02-00115]\] based on MECs in Dutch waters. Second, the average daily use per inhabitant for all these countries was 0.3955 mg TMP, with a range of 0.1937 mg for Greece to 0.5005 mg for the UK. For the last year in the series, the UK still has the highest *per capita* use per day of 0.5056 mg TMP.

Inserting the highest of the above daily use figures for the UK in 2003 into the PEC equation results in a first refined surface water PEC for the UK of 0.253 µg TMP/L. For the European 1995--2003 average use figure the first refined surface water PEC is 0.198 µg/L.

This PEC may be further refined by excretion rate of the parent API including glucuronide or sulfate conjugates, which will be hydrolyzed back to the API in STPs \[[@B75-antibiotics-02-00115]\]. Based on a maximum 20% of ingested TMP being Phase-1-metabolized \[[@B3-antibiotics-02-00115]\], 80% excretion as the parent or its conjugates will be assumed as a worst case; 60% excretion will be assumed as a best case. This results in second refined surface water PECs of 0.202 µg/L for the UK in 2003, respectively of 0.119 µg/L for all European countries for 1995--2003.

A third PEC refinement may be made by incorporating STP removal of TMP. As derived above, based on a minimum of 107 measured removal rates, the average removal of TMP is 25.0% and the median (best case) removal is 30.0% ([Figure 1](#antibiotics-02-00115-f001){ref-type="fig"}). Using the lower, average removal for PEC refinement results in third refined surface water PEC of 0.152 µg/L for the UK in 2003, respectively of 0.089 µg/L for all European countries for 1995--2003. The serial PEC refinements are shown in [Table 1](#antibiotics-02-00115-t009){ref-type="table"}.
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###### 

Surface Water predicted environmental concentrations (PECs) and their Refinement for TMP in Europe.

  PEC stage           Surface water PEC, µg/L   Information used                                                                                           
  ------------------- ------------------------- ---------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------
  Initial crude       2.0                       max daily dose, 400 mg \[[@B4-antibiotics-02-00115]\], EMA ERA guideline \[[@B86-antibiotics-02-00115]\]   
  First refinement    0.253                     0.198                                                                                                      actual daily use per inhabitant, 0.5056 mg (maximum, UK) respectively 0.3955 mg (avg., Europe) (based on \[[@B87-antibiotics-02-00115]\])
  Second refinement   0.202                     0.119                                                                                                      excretion rate, 80% respectively 60%
  Third refinement    0.152                     0.089                                                                                                      STP removal, 25.0% (avg.) respectively 30.0% (median)

Based on the available use, metabolism and STP removal data, a refined surface water PEC range of 0.089--0.152 µg/L seems realistic for Western Europe. This range can be compared with actual surface water MEC data.

### 2.3.2. TMP MECs for Europe

TMP has been measured in European surface waters at least since the mid-1990s and today very many MECs can be located. In total, data representing at least 1899 single MECs have been collated for this ERA; 'at least', because often the number of single analyses is not given and in such cases just one value was assumed. Most of the publicly available MECs (at least 754) are from Germany \[[@B90-antibiotics-02-00115],[@B91-antibiotics-02-00115],[@B92-antibiotics-02-00115],[@B93-antibiotics-02-00115],[@B94-antibiotics-02-00115],[@B95-antibiotics-02-00115],[@B96-antibiotics-02-00115],[@B97-antibiotics-02-00115],[@B98-antibiotics-02-00115],[@B99-antibiotics-02-00115],[@B100-antibiotics-02-00115],[@B101-antibiotics-02-00115],[@B102-antibiotics-02-00115],[@B103-antibiotics-02-00115]\]. Other MECs are from France \[[@B47-antibiotics-02-00115],[@B104-antibiotics-02-00115]\], The Netherlands \[[@B105-antibiotics-02-00115],[@B106-antibiotics-02-00115]\], Spain \[[@B5-antibiotics-02-00115],[@B48-antibiotics-02-00115],[@B107-antibiotics-02-00115],[@B108-antibiotics-02-00115],[@B109-antibiotics-02-00115],[@B110-antibiotics-02-00115]\], Sweden \[[@B44-antibiotics-02-00115],[@B60-antibiotics-02-00115],[@B111-antibiotics-02-00115]\], Switzerland \[[@B112-antibiotics-02-00115],[@B113-antibiotics-02-00115],[@B114-antibiotics-02-00115],[@B115-antibiotics-02-00115],[@B116-antibiotics-02-00115]\], Croatia \[[@B49-antibiotics-02-00115]\] and the United Kingdom \[[@B50-antibiotics-02-00115],[@B117-antibiotics-02-00115],[@B118-antibiotics-02-00115],[@B119-antibiotics-02-00115],[@B120-antibiotics-02-00115]\]. Special thanks to F Bonvin, T Kohn, M Lehmann and M Schärer (see Acknowledgements) for supplying single MEC data that have only been published as overviews.

The values were collated into one single distribution as described by Straub \[[@B121-antibiotics-02-00115],[@B122-antibiotics-02-00115]\] and Metcalfe *et al.* \[[@B123-antibiotics-02-00115]\], detailed in the Experimental Section further below. [Figure 2](#antibiotics-02-00115-f002){ref-type="fig"} is based on at least 1899 back-distributed single measurements that were percent-ranked. Datapoints (blue crosses) were inserted at those concentrations where at least one MEC is either explicitly reported or can be allocated with certainty. In view of many MECs being reported as below the limit of detection or quantitation, there are already a cumulative 8 percentiles of all MECs at 0.001 µg/L, corresponding to an estimated 150 MECs. The 50th and 95th percentiles (MEC~50~ respectively MEC~95~) are indicated in [Figure 2](#antibiotics-02-00115-f002){ref-type="fig"} by drop lines; the MEC~50~ is \~0.012 µg/L, the MEC~95~ \~0.129 µg/L. For comparison, the highest single surface water MEC located in the literature, from the USA \[[@B124-antibiotics-02-00115]\], is 0.710 µg/L (pink cross in [Figure 2](#antibiotics-02-00115-f002){ref-type="fig"}), very close to the highest European MEC of 0.690 µg/L \[[@B109-antibiotics-02-00115]\].

![Compiled European surface water measured environmental concentrations (MECs) for TMP.](antibiotics-02-00115-g002){#antibiotics-02-00115-f002}

It is recognized that this procedure does not deliver exact results but, on the other hand, it is the only possibility of compiling different MEC data into one single distribution and getting a consolidated overview comprising all data, instead of many smaller distributions presented in different formats. Moreover, the more data there are in this distribution, the better will it reflect the actual environmental distribution, in particular at the 95th percentile level, where indeed most references and their respective MEC values are fully integrated already.

### 2.3.3 Comparison of TMP PECs and MECs for Europe

The MEC~95~ and MEC~50~ values lend themselves for comparison with the refined PEC (and alter also the PNEC) values. Recalling the refined PEC range of 0.089--0.152 µg/L, it would seem that the higher PEC is close to the MEC~95~ but that the best-case PEC is a factor of \~7.5 higher than the MEC~50~. Both PECs, however, could actually be too high, possibly for the following reasons.

-   The PECs assume that the whole amount sold is also used and excreted. Patient noncompliance seems to be relatively common, however \[[@B125-antibiotics-02-00115],[@B126-antibiotics-02-00115],[@B127-antibiotics-02-00115]\]. Particularly with antibiotics, some patients stop taking the medicines when they start to feel better, without finishing the whole treatment course. As long as these discarded APIs are not drained into the wastewater, this will reduce the surface water PEC.

-   The PECs assume that the average and median removal rates in STPs derived here are representative for the whole of Europe. Possibly more STPs have well nitrifying AS that results in higher removal and thereby in a lower surface water PEC.

-   The PECs assume a TGD \[[@B79-antibiotics-02-00115]\] default surface water dilution factor of 10. If the average dilution factor in Europe is higher this would result in a lower PEC.

-   The PECs do not factor in environmental degradation beyond the STPs. However, TMP can be degraded by both aerobic and anaerobic biological mechanisms \[[@B30-antibiotics-02-00115],[@B65-antibiotics-02-00115]\] and to some degree by physico-chemical transformation, also in surface waters \[[@B70-antibiotics-02-00115],[@B72-antibiotics-02-00115]\]. Both would reduce the PEC.

2.4. TMP Environmental Effects and Predicted No Effect Concentrations
---------------------------------------------------------------------

### 2.4.1. Micro-organism/STP Inhibition

For STPs to perform their intended function, the AS micro-organisms must not be affected by the micropollutants in the influent. Hence an appraisal of bacterial toxicity of TMP is necessary, the basic data are collated in [Table A6](#antibiotics-02-00115-t006){ref-type="table"} \[[@B15-antibiotics-02-00115],[@B18-antibiotics-02-00115],[@B21-antibiotics-02-00115],[@B29-antibiotics-02-00115],[@B30-antibiotics-02-00115],[@B64-antibiotics-02-00115],[@B128-antibiotics-02-00115],[@B129-antibiotics-02-00115],[@B130-antibiotics-02-00115],[@B131-antibiotics-02-00115],[@B132-antibiotics-02-00115],[@B133-antibiotics-02-00115],[@B134-antibiotics-02-00115],[@B135-antibiotics-02-00115]\].

TMP is not highly toxic to AS bacteria in standard aerobic and anaerobic tests \[[@B18-antibiotics-02-00115],[@B21-antibiotics-02-00115],[@B128-antibiotics-02-00115]\], with EC50 values ranging from 17.8 to \>100 mg/L. Also, in Lumistox tests with the light-emitting marine bacterium *Vibrio fischeri* TMP is not highly toxic, however, toxicity increases with prolonged exposure \[[@B129-antibiotics-02-00115],[@B130-antibiotics-02-00115],[@B131-antibiotics-02-00115]\]. On even longer exposure of 14 days, TMP completely inhibited human nanobacteria at 3.9 mg/L \[[@B132-antibiotics-02-00115]\]; this would be expected as the human therapeutical serum concentration is in the range of 1.5--9 mg/L \[[@B3-antibiotics-02-00115]\]. In a closed bottle ready biodegradation test, no inhibition was noted in the standard toxicity control at 3.25 mg/L TMP-naphthoate, while a significant reduction of colony-forming was noted at 4.6 µg/L TMP-naphthoate \[[@B29-antibiotics-02-00115]\]. This possible discrepancy is not discussed in the paper, however, the toxicity control measures overall inhibition while the colony-forming units relate to cultivable bacterial species. Hence the observations by Alexy *et al.* \[[@B29-antibiotics-02-00115]\] may signify that TMP exerts adverse effects only on certain bacterial species, which may be masked or compensated by the remaining, non-affected species in AS. This interpretation may be supported by the findings of a statistical EC10 in AS of 0.435 mg/L (in contrast to the NOEC observed at 100 mg/L in the same GLP test) \[[@B129-antibiotics-02-00115]\], by NOECs to soil bacteria of 0.02 mg/L \[[@B133-antibiotics-02-00115]\] and to nitrifying bacteria at 0.05 mg/L in one test \[[@B57-antibiotics-02-00115]\], while another nitrification inhibition test under GLP showed no effect at 96 mg/L \[[@B134-antibiotics-02-00115]\]. Moreover, when tested in combination with four other antibiotics (sulfamethoxazole, erythromycin, roxithromycin, clarithromycin; all at the same concentration), TMP reduced the growth of fungi on fallen alder leaves in natural water at 40 µg/L, while at 0.4 µg/L no inhibition was noted \[[@B30-antibiotics-02-00115]\].

Altogether, the above findings are rather difficult to interpret. It seems that TMP can inhibit certain microbial species at concentrations of 4.6 µg/L (LOEC) \[[@B29-antibiotics-02-00115]\] while other bacteria are not adversely affected at concentrations over 100 mg/L \[[@B21-antibiotics-02-00115]\]. In an STP, the latter may take over some of the ecological functions of the affected species, as suggested by the AS respiration inhibition and nitrification inhibitions tests (both relying on overall functional endpoints), and thereby compensate functionally for the inhibited micro-organisms. This is supported by the observation that biodegradation (not only of TMP itself but in general) and nitrification in working STPs is not significantly inhibited by the influent concentrations of TMP and many other substances, as shown by overall functional parameters. Therefore, TMP may cause inhibition of specific bacteria and potentially shifts in species compositions at concentrations between 4.6 and 0.4 µg/L, but at current uses there is no evidence of adverse effects on the functions of STPs. This may also be related to a certain tolerance (or resistance) of STP bacterial communities toward many different micropollutants including TMP.

Similarly, Liu *et al.* \[[@B135-antibiotics-02-00115]\] found in an experiment with spiked natural soil that TMP decreases the total soil respiration in comparison with a blank control during the first 4 days of exposure from 20 mg TMP/kg soil (dry weight), whereas from day 5 to the end of the assay at day 21 no inhibition was noted, but either no change or increased respiration at all concentrations up to the highest of 300 mg TMP/kg soil (dry weight). This was interpreted as an initial overall inhibition followed by an adaptation of the collective of aerobic micro-organisms. In this work, Liu *et al.* \[[@B135-antibiotics-02-00115]\] note a soil dissipation half-time (DT50) of 2--5 days for TMP and in a later publication the same group \[[@B15-antibiotics-02-00115]\] gives a DT50 in aerobic soil of 4 days, which suggests that after about half of the spiked TMP is removed (by biodegradation or bound residue formation) the bacterial community adapts to the substance. In view of the very general endpoint of total respiration a persistent inhibition of certain species is still conceivable, but the ongoing dissipation of TMP in the soil through mainly biodegradation \[[@B15-antibiotics-02-00115]\] suggests that in such a case at least the biodegradation functionality can be compensated by the remaining bacteria.

### 2.4.2. Surface Water Ecotoxicity

For the appraisal of surface water ecotoxicity there are two extensive datasets for TMP, one acute ([Table A7](#antibiotics-02-00115-t007){ref-type="table"}) and one chronic ([Table A8](#antibiotics-02-00115-t008){ref-type="table"}). The acute dataset fully rests on published and some older Roche-internal tests (which are already used for the Roche safety data sheets) while for the chronic dataset some new tests performed specifically for this ERA are reported for the first time.

#### 2.4.2.1. Acute Ecotoxicity of TMP ([Table A7](#antibiotics-02-00115-t007){ref-type="table"}) \[[@B9-antibiotics-02-00115],[@B18-antibiotics-02-00115],[@B124-antibiotics-02-00115],[@B129-antibiotics-02-00115],[@B130-antibiotics-02-00115],[@B136-antibiotics-02-00115],[@B137-antibiotics-02-00115],[@B138-antibiotics-02-00115],[@B139-antibiotics-02-00115],[@B140-antibiotics-02-00115],[@B141-antibiotics-02-00115],[@B142-antibiotics-02-00115],[@B143-antibiotics-02-00115],[@B144-antibiotics-02-00115],[@B145-antibiotics-02-00115],[@B146-antibiotics-02-00115],[@B147-antibiotics-02-00115],[@B148-antibiotics-02-00115],[@B149-antibiotics-02-00115],[@B150-antibiotics-02-00115]\]

Acute data exist for cyanobacteria, algae, hydrozoans, rotifers, crustaceans, molluscs, flowering plants and fish. The acute EC50 or LC50 data range from 5.1 mg/L for a marine alga (where TMP would be mostly non-dissociated in view of the basic *p*H of seawater) \[[@B137-antibiotics-02-00115]\] to 296 mg/L for daphnids \[[@B149-antibiotics-02-00115]\] for those tests where a concise value is given (*i.e.*, not a '\>highest tested concentration'). For fish in particular, all highest tested concentrations did not result in an LC50, which would be expected in view of the fact that fish are not intended to be target organisms for antibiotics. The one apparent exception to this is an LC50 value of 3 mg/L cited by Kolpin *et al.* \[[@B124-antibiotics-02-00115]\], which proves to be a miscitation: The original paper by Bergsjø *et al.* \[[@B80-antibiotics-02-00115]\], which is actually referred to by Kolpin *et al.* \[[@B124-antibiotics-02-00115]\], gives a single oral dose of approximately 0.02 mg radio-labelled TMP per gram of fish, but not a concentration. Moreover, none of the fish used is reported by Bergsjø *et al.* \[[@B80-antibiotics-02-00115]\] to have died of TMP. Hence, this erroneous citation is not used for toxicity assessment.

Antibiotics are used to inhibit bacterial infections, which is why Holten Lützhøft *et al.* \[[@B138-antibiotics-02-00115]\] noted that 'to perform a proper environmental risk assessment of antibacterial agents, it would be necessary to include a cyanobacteria as test organism in the test battery'; this request has been adopted in the EMA guideline for ERA of human APIs \[[@B86-antibiotics-02-00115]\]. But at least in the case of TMP the cyanobacterian species tested are neither the most sensitive nor is the range of cyanobacterian EC50s limited to low concentrations; on the contrary, the EC50s range from 11 to \>200 mg/L \[[@B136-antibiotics-02-00115],[@B138-antibiotics-02-00115]\]. This may suggest that for some reason TMP is not as highly toxic to cyanobacteria than to human nanobacteria \[[@B132-antibiotics-02-00115]\]; possibly, photosynthetic cyanobacteria are not as dependent on their own *de novo* folate biosynthesis as human pathogenic bacteria. By extension, the comparatively high threshold for ecotoxicological effects over the broad array of groups and species tested confirms the statement by Blaise *et al.* \[[@B129-antibiotics-02-00115]\] that TMP is relatively nontoxic.

#### 2.4.2.2. Chronic Ecotoxicity of TMP ([Table A8](#antibiotics-02-00115-t008){ref-type="table"}) \[[@B136-antibiotics-02-00115],[@B137-antibiotics-02-00115],[@B139-antibiotics-02-00115],[@B140-antibiotics-02-00115],[@B141-antibiotics-02-00115],[@B142-antibiotics-02-00115],[@B143-antibiotics-02-00115],[@B144-antibiotics-02-00115],[@B145-antibiotics-02-00115],[@B146-antibiotics-02-00115],[@B151-antibiotics-02-00115],[@B152-antibiotics-02-00115],[@B153-antibiotics-02-00115],[@B154-antibiotics-02-00115]\]

The new chronic tests under GLP quality assurance commissioned with the aquatic flowering plant *Lemna minor* \[[@B143-antibiotics-02-00115]\] and the zebrafish *Danio rerio* \[[@B153-antibiotics-02-00115]\] bring the total number of systematic groups tested chronically to 8 (including the three standard groups algae, daphnids and fish) and the number of species to 17. Once more, the marine alga that was already the most sensitive on an acute scale has the lowest EC50 \[[@B137-antibiotics-02-00115]\], which (again as expected) suggests that TMP would be more toxic while mostly non-dissociated in view of the basic *p*H of seawater. Also on a chronic level the cyanobacterians have a wide range of NOECs, from 3.1 to ≥200 mg/L \[[@B136-antibiotics-02-00115]\].

A FETAX larval test with the toad *Xenopus laevis* is included among the chronic data despite the short duration, as this test takes place during a very sensitive phase of development and has therefore been accepted as chronic by the recent EU Technical Guidance Document for Deriving Environmental Quality Standards (EQS) in the scope of the EU Water Framework Directive \[[@B155-antibiotics-02-00115]\]. Together with the new zebrafish early life stage NOEC at the highest tested concentration of 100 mg/L \[[@B153-antibiotics-02-00115]\], the fish and amphibian data once more suggest that vertebrates are not particularly sensitive to TMP and that generally speaking, also on a chronic level TMP is relatively nontoxic \[[@B129-antibiotics-02-00115]\] as well.

2.5. TMP Predicted No Effect Concentrations
-------------------------------------------

### 2.5.1. Deterministic TMP PNEC Derivation

This copious compilation of acute and chronic ecotoxicity data allows for both a solid deterministic and a well-founded probabilistic PNEC or HC5 (hazardous concentration for 5% of species tested) according to the requirements of the TGD \[[@B79-antibiotics-02-00115]\]. Where more than one result was available for the same species, the geometrical average was calculated and this will be used for PNEC derivation, in line with the EU EQS derivation guidance \[[@B155-antibiotics-02-00115]\]. According to the TGD \[[@B79-antibiotics-02-00115]\], when at least three endpoints are available for a minimum dataset of algae, daphnids and fish, the acute deterministic PNEC is the lowest EC50 or LC50 divided by an assessment factor (AF) of 1000; the chronic deterministic PNEC is the lowest NOEC or EC10 divided by an AF of 10.

The lowest chronic value retrieved, a NOEC of ≥1 mg/L (the highest tested concentration) for the duckweed *Lemna gibba* \[[@B142-antibiotics-02-00115]\] will not be used for deterministic or probabilistic PNEC derivation, however, because (a) basing a PNEC on a lower bound of a NOEC generates a high uncertainty in general, in particular (b) because from a '≥' value no unambiguous deterministic or probabilistic PNEC can be derived, but again only a '≥' value, and (c) because the closely related *Lemna minor* showed a clear NOEC of 53.5 mg/L in a GLP test \[[@B143-antibiotics-02-00115]\] with measured exposure concentrations, about 50 times higher than the disputed value.

In addition, other, very low, highest tested concentrations published without any biological effects noted whatsoever, like the above value in Brain *et al.* 2004 \[[@B142-antibiotics-02-00115]\], were not used. This concerns the daphnid NOEC of 10 µg/L (highest tested concentration) published by Flaherty & Dodson 2005 \[[@B152-antibiotics-02-00115]\], which included the endpoints survival, adult and neonate morphology, ephippium production, fecundity and offspring sex ratio. However, it was based on a duration of only 6 days, whereas the OECD guideline stipulates 21 days, and was therefore not used for derivation of PNECs. Also, in a recent test with the marine rotifer *Brachionus koreanus*, Rhee *et al.* \[[@B145-antibiotics-02-00115]\] tested nominal concentrations of 10 and 100 µg/L TMP for 10 days and noted 'gradual' or 'slight growth retardation' \[[@B145-antibiotics-02-00115]\] (pp. 109 and 116, respectively) at 100 µg/L. However, while a slight retardation in growth may be seen from their graph on p 115, Rhee and colleagues do not comment on the fact that TMP-exposed *Brachionus* seem to fully compensate their delayed reproduction by the end of the test on day 10, when the error bars of controls and the two tested concentrations overlap. As the test runs over ten days, as there is no significant adverse effect at the end of the test and as the authors did not test sufficiently high concentrations to unambiguously demonstrate such an effect, this endpoint will not be used here.

Last, the biomarker data for the zebra mussel *Dreissena polymorpha* published by Binelli *et al.* \[[@B156-antibiotics-02-00115]\] are not used for PNEC derivation, either, as the acute-based NOEC is based on ambiguous inhibition or mortality endpoints. The same holds for the biomarker endpoints in the rotifer paper by Rhee and colleagues \[[@B145-antibiotics-02-00115]\]. For the time being there is no regulatory guidance on extrapolation from biomarker responses to organism- or population-relevant endpoints that may be used within the scope of an ERA. Rejecting them for the PNEC derivation is in line with the EU EQS guidance document \[[@B155-antibiotics-02-00115]\] which states that 'data from studies describing endpoints that do not include direct measurements of survival, development or reproduction but, rather, describe e.g., behavioral effects, anatomical differences between control and treatment groups, *effects at the tissue or sub-cellular level, such as changes in enzyme induction or gene expression* ... generally ... are unsuitable as the basis for EQS derivation'.

Based on these provisions the deterministic acute-based aquatic PNEC for TMP is 5.1 µg/L, derived from the marine algal EC50 of 5.1 mg/L (*Phaeodactylum tricornutum*) \[[@B137-antibiotics-02-00115]\], applying an AF of 1000. Also the deterministic chronic aquatic PNEC of 240 µg/L relies on the same algal species with a NOEC of 2.4 mg/L \[[@B137-antibiotics-02-00115]\] and an AF of 10. The chronic-based PNEC is considered more relevant in view of reflecting long-term, continuous exposure. However, the fact that the most sensitive organism for both the acute and chronic endpoints is a marine alga, suggests that the high *p*H of seawater renders TMP more toxic due to a higher non-dissociated fraction, beside the algae-typical phenomenon of ion trapping \[[@B157-antibiotics-02-00115]\].

### 2.5.2 Probabilistic PNEC Derivations

#### 2.5.2.1. TGD Probabilistic PNEC

The first probabilistic PNEC was derived as described in the EU TGD \[[@B79-antibiotics-02-00115]\] by calculating the HC5 or 5th percentile of the chronic NOECs distribution and dividing this figure by an additional AF between 1 and 5. While there is some information given on the choice of this additional AF, no unequivocal, hard criteria exist. Hence for this ERA, a range for the chronic probabilistic PNEC will be given, from HC5/5 to HC5. The HC5 calculated by Excel is 2.93 mg/L, therefore the probabilistic PNEC range is 586--2,930 µg/L, with an average of 1,758 µg/L. The derivation of the PNECs is shown graphically in [Figure 3](#antibiotics-02-00115-f003){ref-type="fig"}.

![Acute and chronic ecotoxicity data, deterministic and probabilistic predicted no effect concentrations (PNECs) for TMP.](antibiotics-02-00115-g003){#antibiotics-02-00115-f003}

In [Figure 3](#antibiotics-02-00115-f003){ref-type="fig"}, the acute aquatic EC50/LC50 values (red dots) and chronic aquatic NOEC values (filled dark green triangles) for TMP are shown, both percent-ranked and plotted on a log-probabilistic scale, with deterministic PNECs (open symbols; AF 1000 for acute data, AF 10 for chronic NOECs) and the light green TGD-calculated probabilistic PNEC band ranging from HC5÷5 (586 µg/L) to the HC5 (2,930 µg/L).

#### 2.5.2.2. Webfram Probabilistic HC5

In addition to the TGD probabilistic PNEC, the chronic NOECs were entered into the Webfram application (<http://www.webfram.com>) \[[@B158-antibiotics-02-00115]\], which calculates a probabilistic HC5 based on a Bayesian algorithm \[[@B159-antibiotics-02-00115]\]. Moreover, Webfram also computes goodness-of-fit values according to Kolmogorov-Smirnov, Cramer-Von Mises and Anderson-Darling algorithms; for all three tests the goodness-of-fit of the chronic TMP NOECs is accepted at a *p* value of 0.01. The probabilistic HC5 as determined by Webfram is 1,778 µg/L, with a 95% confidence interval between 334 and 4,832 µg/L ([Figure 4](#antibiotics-02-00115-f004){ref-type="fig"}). This HC5 compares nicely with the average of the EU probabilistic PNEC range, 1,758 µg/L.

![Webfram: chronic aquatic NOEC values and HC5. Chronic aquatic NOEC values (black dots) for TMP, percent-ranked and plotted by Webfram on a log-probabilistic scale; the 95% confidence interval is given as dashed lines. The Webfram-calculated probabilistic HC5 is 1,778 µg/L (middle green arrow) and the 95% confidence interval for the HC5 lies between 334 and 4,832 µg/L (left and right green arrows).](antibiotics-02-00115-g004){#antibiotics-02-00115-f004}

2.6. Aquatic Environmental Risk Assessment for Human-Use TMP in Europe
----------------------------------------------------------------------

### 2.6.1. TMP Risk Characterization Ratios

With sufficient exposure and effects information, both transformed into PECs or MECs and PNECs, the formal ERA for the surface waters in Europe can now be addressed. The various PECs and compiled MECs are compared with the PNECs in [Table 2](#antibiotics-02-00115-t010){ref-type="table"}.

All risk characterization ratios without exception are \<1, which means no significant risk overall. In particular, all risk characterization ratios that use any chronic-based, deterministic or probabilistic PNEC, which is taken to better reflect the permanent exposure to APIs, range from \<0.01 to \<0.00001. This firmly corroborates the first conclusion of no significant risk from TMP in surface waters in Europe and beyond.
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###### 

TMP risk assessment for European surface waters: PECs, MECs, PNECs and PEC/PNEC and MEC/PNEC risk characterization ratios respectively margins of safety.

  Environmental concentrations (PECs and MECs)                                           Predicted no-effect concentrations (PNECs)   Risk ratio (PEC/PNEC or MEC/PNEC)   Margin of safety (inverse of risk ratio)                    
  -------------------------------------------------------------------------------------- -------------------------------------------- ----------------------------------- ------------------------------------------ ---------------- ------------
  **Derivation**                                                                         **value, µg/L**                              **Derivation**                      **value, µg/L**                                             
  EMA crude PEC                                                                          2.0                                          acute-det                           5.1                                        0.392            2.55
  2.0                                                                                    chronic-det                                  240                                 0.00833                                    120              
  2.0                                                                                    chronic-pr                                   586--2930                           0.00341--0.000683                          293--1465        
  2.0                                                                                    Webfram pr HC5                               1778                                0.00112                                    889              
  Third refined PEC (incl. actual use, excretion rate, STP removal) \[this work\]        0.152--0.089                                 acute-det                           5.1                                        0.0299--0.0175   33.6--57.3
  0.152--0.089                                                                           chronic-det                                  240                                 0.000633--0.000371                         1579--2697       
  0.152--0.089                                                                           chronic-pr                                   586--2930                           0.000259--0.0000304                        3855--32921      
  0.152--0.089                                                                           Webfram pr HC5                               1778                                0.0000855--0.0000500                       11697--19978     
  European MEC95 \[this work, [Figure 2](#antibiotics-02-00115-f002){ref-type="fig"}\]   0.129                                        acute-det                           5.1                                        0.0253           39.5
  0.129                                                                                  chronic-det                                  240                                 0.000538                                   1860             
  0.129                                                                                  chronic-pr                                   586--2930                           0.000220--0.0000440                        4543--22713      
  0.129                                                                                  Webfram pr HC5                               1778                                0.0000726                                  13783            
  European MEC50 \[this work, [Figure 2](#antibiotics-02-00115-f002){ref-type="fig"}\]   0.012                                        acute-det                           5.1                                        0.00235          425
  0.012                                                                                  chronic-det                                  240                                 0.00005                                    20000            
  0.012                                                                                  chronic-pr                                   586--2930                           0.0000205--0.0000041                       48833--244167    
  0.012                                                                                  Webfram pr HC5                               1778                                0.00000675                                 148167           
  Maximum European MEC \[[@B109-antibiotics-02-00115]\]                                  0.690                                        acute-det                           5.1                                        0.135            7.39
  0.690                                                                                  chronic-det                                  240                                 0.00286                                    348              
  0.690                                                                                  chronic-pr                                   586--2930                           0.00118--0.000235                          849--4246        
  0.690                                                                                  Webfram HC5                                  1778                                0.000388                                   2577             
  Maximum MEC located worldwide, USA \[[@B124-antibiotics-02-00115]\]                    0.710                                        acute-det                           5.1                                        0.139            7.18
  0.710                                                                                  chronic-det                                  240                                 0.00296                                    338              
  0.710                                                                                  chronic-pr                                   586--2930                           0.00121--0.000242                          825--4127        
  0.710                                                                                  Webfram pr HC5                               1778                                0.000399                                   2504             

### 2.6.2. TMP Risk Graph

The whole information for this ERA including the margins of safety determined here can also be illustrated in one single risk graph for TMP ([Figure 5](#antibiotics-02-00115-f005){ref-type="fig"}).

In the risk graph ([Figure 5](#antibiotics-02-00115-f005){ref-type="fig"}) the whole exposure and effects information for TMP is brought together. Acute aquatic EC50/LC50 data are shown as red dots, with the derivation of the deterministic PNEC of 5.1 µg/L (hollow red circle) by application of an assessment factor (AF) of 1000. Chronic aquatic NOEC values are shown as filled dark green triangles, with the derivation of the deterministic chronic PNEC of 240 µg/L (hollow green triangle) by application of an AF of 10. Further, the bright green probabilistic TGD chronic PNEC band ranging from 586 to 2,930 µg/L is depicted as well as the Webfram-calculated HC5 of 1,778 µg/L (green star in the band). European MECs are shown by dark blue crosses, with the European MEC~95~ at 0.129 µg/L; in addition, the highest MEC from the USA of 0.710 µg/L is shown as a pink cross. For illustration, selected margins of safety (MOS) are shown by horizontal arrows from the MEC~95~ to the corresponding PNECs.

![TMP risk graph for European surface waters.](antibiotics-02-00115-g005){#antibiotics-02-00115-f005}

Beyond the MOSs between the MEC95 for Europe and selected PNECs, the risk graph also shows very clearly that, at least within the confines of the 1st and 99.95th percentiles, the MEC regression lines and the chronic NOECs regression line do not overlap. This illustrates graphically that there is no perceivable risk. In view of the fact that TMP use has been declining in Europe over the past 10--15 years, this conclusion is further strengthened.

### 2.6.3. Limitations of the Present TMP ERA

#### 2.6.3.1. Mixture Assessment

Synergistic or cocktail effects arising from the exposure to many micropollutants, comprising not only APIs but quite a diverse group of substances, are not included in this ERA. However, the data collated and presented here can serve for developing the TMP ERA further to include at least some other APIs, mainly sulfamethoxazole or other sulfonamides, with which TMP is often combined. But while some aspects of mixtures ERA are reasonably well understood \[[@B160-antibiotics-02-00115]\], it is not easy to do a combined ERA for a few substances and it becomes practically impossible to do it for a large number. Hence, the present TMP ERA does not address mixture toxicity.

#### 2.6.3.2. Human Plus Veterinary Use of TMP

The PECs on which this ERA relies only refer to human use of TMP. But TMP is also used on a large scale for veterinary purposes, again mostly in combination with sulfonamides. While total European quantitative data are not readily available, there are both veterinary and human use data published for Denmark over the past 15 years (DANMAP) \[[@B161-antibiotics-02-00115]\]. Denmark is a European country with intense agricultural production, both of farm animals like pigs, cows or poultry as well as of fish in freshwater and marine aquaculture. Hence, extrapolating from the Danish data to the European level is judged to add a worst-case exposure from animal use of TMP. DANMAP 2012 data show that the total veterinary usage of TMP plus sulfonamides has been rising in the decade from 2001 to 2010, with a maximum of 14,950 kg in 2009 and the 2010 figure at 13,900 kg. Assuming also a 5:1 ratio of veterinary sulfonamides to TMP (as with human sulfamethoxazole and TMP in Bactrim) would translate to an annual veterinay use of 2,333 kg TMP for Denmark. Specifically for aquaculture, 3,060 kg antimicrobials were used in 2010, of which 66% or 2,020 kg sulfonamides plus TMP, which again corresponds to 337 kg TMP for direct aquatic usage and 1,996 kg TMP (2,333 minus 337) for mammals and poultry. On the human-use side, in 2010, 417 kg TMP and derivatives were used beside 252 kg of sulfonamides plus TMP, which latter amount translates to 42 kg TMP, hence a total of 459 kg TMP from human use. Assuming that the farm animal use will not get directly into surface waters and therefore adding only the aquaculture TMP, which is used directly in water, to the total human use, results in a supplement of 337 kg to the 459 kg, or 73% more. Hence, as a very crude worst-case extrapolation, 173% of the human-use PECs will be used as an overall surface water PEC from human plus veterinary use for ERA. Multiplying the various PECs in [Table 2](#antibiotics-02-00115-t010){ref-type="table"} (above) with a factor of 1.73 will increase the PEC/PNEC ratios, but even for the rather unrealistic EMA crude PEC of 2.0 µg/L, now increased to 3.46 µg/L, the acute-based risk characterization ratio is still \<1; it is still lower by dimensions for the MECs (which at least for Denmark include that part of veterinary TMP that ends up in surface waters) as well as for chronic PNECs. Hence, even including a reasonable worst-case contribution from veterinary use to aquatic TMP PECs will not lead to a significant surface water risk.

#### 2.6.3.3. Antibiotic Resistance

Another topic that is far beyond the scope of this ERA is antibiotic resistance development or maintenance due to the presence of antibiotics like TMP in STPs, surface waters or other environmental compartments \[[@B162-antibiotics-02-00115],[@B163-antibiotics-02-00115]\]. While multi-antibiotic resistance has been shown for certain environmental compartments, notably sewage treatment, surface waters and soils \[[@B164-antibiotics-02-00115],[@B165-antibiotics-02-00115]\], it is difficult to causally relate solely the presence of antibiotics (as opposed to the input of resistant bacteria from human patients or livestock) to the development or maintenance of such resistance. Indeed, some researchers found no maintenance, but on the contrary loss, of resistance in a laboratory sewage treatment plant despite the continued presence of antibiotics \[[@B166-antibiotics-02-00115]\]. Moreover, so far there is no accepted regulatory methodology to assess this question. Hence, the question of potential resistance must remain for other investigations.

#### 2.6.3.4. Further Environmental Compartments

According to the TGD ERA methodology \[[@B79-antibiotics-02-00115]\], substances may be transferred from wastewater to the soil by way of land-spreading of surplus sewage sludge and from surface water to sediment by partitioning or to groundwater by infiltration. For all of these pathways there are insufficient data for a serious assessment of TMP, both on the environmental fate, distribution, partitioning or MEC side and in particular on the effects side in the receiving compartments. In view of this situation, no attempt will be made to characterize risk for these compartments by discussing the meager data or by read-across.

3. Experimental
===============

3.1. Literature Search
----------------------

Environmentally relevant peer-reviewed and non-reviewed ('grey') literature for TMP was searched for using dedicated search engines on the internet (ACS SciFinder, Google Scholar, chemical data collections like OECD Chemicals Portal <http://www.echemportal.org/> or the European Union Chemical Substances Information System <http://esis.jrc.ec.europa.eu/> as well as safety data sheet search engines such as <https://www.eusdb.de>), beside company-internal substance documentation and archives. The information was sighted, ordered and collated. Reference lists in the retrieved documents often allowed to supplement the literature dataset with further, mostly older publications and also online sources for MECs.

3.2. Collation of STP Removal Rates and Surface Water MECs
----------------------------------------------------------

All retrieved published STP removal rates, *viz.*effluent concentration as a percentage of influent concentration, worldwide were entered into a spreadsheet with removal rates ranging from −550% (the highest negative removal reported, which eventually was not used in the analysis, see argument on page 118) to 100% removal, with a value of 1 per documented removal rate into one column per each reference. All rates were horizontally added to a total per removal rate in per cent. Then, these values were multiplied by 100 and divided by the known total number of removal rates plus 1, in a percent-ranking procedure. Then, a plot was drawn using SigmaPlot 12 software (Scistat, Inc., San Jose, CA, USA) with the percentiles on a probabilistic ordinate and the removal rates on a linear abscissa. The average and median removal rates were determined by excel spreadsheet functions.

All reported, discrete, single European surface water MECs were entered into one column per reference into a spreadsheet with a 1-ng/L-gradation ranging from ≤1 ng/L up to 1,000 ng/L. Then, the remaining (non-specified) MEC data were back-distributed per publication into the same column, based on total number of analyses, number below LOQ, between LOQ and median, between median and 90th percentile and between 90th percentile and the maximum value, to an average expected fraction or number of detections per ng/L-gradation for these ranges. For instance, if the LOQ in a particular publication was 5 ng/L and there were 7 MECs \<LOQ, 7 was divided by 5 and the resulting fraction of 1.4 was entered into all 5 gradations from ≤1 to ≤5. Similarly, the number of MECs given between LOQ and the median, or between the median and the 75th or 90th percentile if indicated, were back-distributed. Then, both the precisely known numbers and the expected, back-distributed fractions of detections were horizontally added per ng/L-gradation, multiplied by 100 and divided by the known total number of analyses plus 1, in a percent-ranking procedure. This procedure resulted in a theoretical 690 values computed, 0.690 µg/L being the highest published surface water MEC in Europe, from a series that sampled only 100 m downstream of sewage works effluents in Madrid Region \[[@B109-antibiotics-02-00115]\]. Out of these 690 values, however, only those values were kept for plotting and graphical regression where at least one actual analytical detection was certain. The plot was drawn using SigmaPlot software with a probabilistic ordinate and a logarithmic abscissa. The associated regression line then allows the graphical estimation of the overall 50th and 95th percentile MEC values (MEC~50~ respectively MEC~95~) based on at least 1899 single European MECs ([Figure 2](#antibiotics-02-00115-f002){ref-type="fig"}).

3.3. Identification of Ecotoxicity Data Gaps and Additional Ecotoxicity Studies
-------------------------------------------------------------------------------

Based on the chronic aquatic ecotoxicity dataset retrieved and critically analyzed, it was found that chronic fish studies were totally lacking and that a chronic study with the angiosperm *Lemna gibba* \[[@B142-antibiotics-02-00115]\] was not adequate for risk assessment as the NOEC found was the highest tested concentration. To fill these data gaps, two additional chronic ecotoxicity studies with the duckweed *Lemna minor* following OECD test guideline 221 \[[@B143-antibiotics-02-00115]\] and the zebrafish *Danio rerio* following OECD TG 210 were commissioned at reliable contract labs. Moreover, an activated sludge respiration inhibition test according to OECD TG 209 \[[@B128-antibiotics-02-00115]\] and a dedicated activated sludge nitrification inhibition test following ISO TG 9509 \[[@B134-antibiotics-02-00115]\] were also made. All newly commissioned tests were performed under GLP quality assurance, in the cases of the duckweed growth inhibition and the fish early life stage tests also with full analytical determination of the exposure concentrations by HPLC and statistical determinations of EC~10~ and EC~50~s as applicable, beside the NOECs. All additional tests were financed by Roche.

3.4. Risk Assessment Methodology
--------------------------------

Deterministic and probabilistic ERA methods were applied, following the EU TGD \[[@B79-antibiotics-02-00115]\] for both acute- and chronic-based deterministic PNEC derivation as well as for TGD probabilistic PNEC band calculation. Additionally, the Webfram online tool (<http://www.webfram.com>) \[[@B158-antibiotics-02-00115]\] was used for deriving a second probabilistic PNEC or HC~5~ based on a Bayesian algorithm.

4. Conclusions
==============

An extended ERA was developed for the aquatic compartment in Europe for the old antibiotic TMP from human use. This ERA relies on both crude and refined surface water PECs for TMP, the latter integrating actual use figures, human metabolism and documented STP removal rates; these PECs range from the crude EMA PEC of 2 µg/L to the third refined PEC of 0.089 µg/L. The PECs are complemented by a veritable host of at least 1899 single MECs from European countries that were compiled into one distribution, allowing the approximation of median (0.012 µg/L) and 95th percentile (0.129 µg/L) values for surface water concentrations, with the European maximum at 0.690 µg/L.

On the environmental effects side, existing and newly developed ecotoxicity data were used to derive deterministic acute and chronic PNECs of 5.1 respectively 240 µg/L. The 16 chronic data from 8 different systematic groups were also used to derive a probabilistic PNEC range of 586--2,930 µg/L (EU TGD) or a probabilistic HC5 (PNEC) value of 1,778 µg/L (95% CI: 334--4,832 µg/L; Webfram). All acute (EC50/LC50) and chronic (NOEC/EC10) ecotoxicity data for cyanobacteria, green algae, marine algae, angiosperms, hydrozoans, rotifers, crustaceans, fish and amphibians are above 1 mg/L, supporting low ecotoxicity for TMP.

All PEC/PNEC or MEC/PNEC risk characterization ratios are \<1, all of the chronic-based risk ratios are \<0.01 to \<\<0.01, showing no indication of risk due to the presence of TMP in surface waters.

Moreover, while the available data suggest that TMP is persistent in surface waters, there is no evidence that TMP bioaccumulates and there are no experimental ecotoxicity data that suggest inordinately high toxicity; hence TMP is not a PBT substance, either.

Based on this extended ERA, no significant risk is seen for TMP from human use in the aquatic compartment in Europe.

Insufficient environmental fate and effects data were available for a reasonably well founded ERA for the compartments sediment and soil, but evidence is given that these two compartments in all probability are not central for TMP from human use. Also, there is a plausibility presentation that the additional veterinary use of TMP does not lead to significantly increased surface water levels and thus not to significant increased risk. The issues of mixture toxicity and antibiotic resistance could not be addressed based on available data and risk assessment procedures.
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antibiotics-02-00115-t001_Table 1

###### 

Physico-Chemical Data for TMP.

  Property                                 Method                                       Value                                                                Unit                  Reference
  ---------------------------------------- -------------------------------------------- -------------------------------------------------------------------- --------------------- ----------------------------------------------------------------
  CAS number                                                                            738-70-5                                                                                   SDS Roche \[[@B2-antibiotics-02-00115]\]
  Molecular mass                                                                        290.32                                                               g/mol                 SDS Roche \[[@B2-antibiotics-02-00115]\]
  Melting point                            experimental                                 199--203                                                             °C                    SDS Roche \[[@B2-antibiotics-02-00115]\]
  Vapour pressure                          experimental                                 9.88 × 10^--9^ = 1.32 × 10^--6^                                      mm Hg Pa              Gros *et al.* 2006 \[[@B5-antibiotics-02-00115]\]
  Water solubility                         experimental                                 400                                                                  mg/L, 25 °C           PhysProp online \[[@B6-antibiotics-02-00115]\]
                                           experimental                                 400                                                                  mg/L                  Chen *et al.* 2002 \[[@B7-antibiotics-02-00115]\]
                                           experimental                                 401                                                                  mg/L                  Ran *et al.* 2002 \[[@B8-antibiotics-02-00115]\]
                                           experimental                                 300                                                                  mg/L                  SDS Roche \[[@B2-antibiotics-02-00115]\]
                                           experimental, freshwater & marine            \~75 (both)                                                          mg/L                  Bergsjø & Søgnen 1980 \[[@B9-antibiotics-02-00115]\]
  Dissociation constant                    experimental                                 7.6                                                                  base pKa              Bergsjø & Søgnen 1980 \[[@B9-antibiotics-02-00115]\]
                                           experimental                                 7.2; 6.6                                                             base pKa              Clarke's online \[[@B3-antibiotics-02-00115]\]
                                           experimental                                 6.6                                                                  base pKa              Roche SDS \[[@B2-antibiotics-02-00115]\]
                                           experimental                                 6.76 ± 0.12; 3.23 ± 0.30                                             base pKa1 base pKa2   Qiang & Adams 2004 \[[@B10-antibiotics-02-00115]\]
  Octanol/water partition coefficient      experimental                                 0.64                                                                 logKow                Roche SDS \[[@B2-antibiotics-02-00115]\]
                                           experimental                                 0.74, *p*H 7.4                                                       logD                  Zhu *et al.* 2002 \[[@B11-antibiotics-02-00115]\]
                                           experimental                                 0.91                                                                 logKow                PhysProp online \[[@B6-antibiotics-02-00115]\]
                                           experimental                                 1.115                                                                logKow                Zhao *et al.* 2002 \[[@B12-antibiotics-02-00115]\]
  Adsorption to organic carbon, Koc        experimental                                 1680--3990                                                           L/kg                  Boxall *et al.* 2005 \[[@B13-antibiotics-02-00115]\]
  Koc, digested sludge                     experimental                                 724 (logKoc = 2.86)                                                  L/kg                  Barron *et al.* 2009 \[[@B14-antibiotics-02-00115]\]
  Koc, soil                                experimental                                 224 (logKoc = 2.35)                                                  L/kg                  Barron *et al.* 2009 \[[@B14-antibiotics-02-00115]\]
  Koc, soil                                experimental, soil *p*H 4.9                  719                                                                  L/kg                  Liu *et al.* 2010 \[[@B15-antibiotics-02-00115]\]
  Koc, soil                                experimental                                 4600                                                                 L/kg                  Lin & Gan 2011 \[[@B16-antibiotics-02-00115]\]
  Koc                                      QSAR estimate                                2692                                                                 L/kg                  Franco & Trapp 2010 \[[@B17-antibiotics-02-00115]\]
  Sorption (Kd) to activated sludge (AS)   experimental                                 76                                                                   L/kg                  Halling-Sørensen *et al.* 2000 \[[@B18-antibiotics-02-00115]\]
  Kd, AS                                   experimental                                 208 ± 49                                                             L/kg                  Göbel *et al.* 2005 \[[@B19-antibiotics-02-00115]\]
  Kd, AS                                   experimental                                 \~200--300                                                           L/kg                  McArdell *et al.* 2005 \[[@B20-antibiotics-02-00115]\]
  Kd, AS                                   experimental inherent bodegradability test   \~1500 (3 h), \~966 (28 d)                                           L/kg                  Gartiser *et al.* 2007 \[[@B21-antibiotics-02-00115]\]
  Kd, AS                                   experimental                                 330 ± 25                                                             L/kg                  Abegglen *et al.* 2009 \[[@B22-antibiotics-02-00115]\]
  Kd, digested sludge                      experimental                                 68                                                                   L/kg                  Barron *et al.* 2009 \[[@B14-antibiotics-02-00115]\]
  Kd, primary sludge                       experimental                                 427 ± 238                                                            L/kg                  Radjenovic *et al.* 2009 \[[@B23-antibiotics-02-00115]\]
  Kd, AS                                   experimental                                 253 ± 37                                                             L/kg                  Radjenovic *et al.* 2009 \[[@B23-antibiotics-02-00115]\]
  Kd, membrane bioreactor                  experimental 2 MBRs                          225 ± 87; 320 ± 117                                                  L/kg                  Radjenovic *et al.* 2009 \[[@B23-antibiotics-02-00115]\]
  Kd, AS                                   experimental                                 68                                                                   L/kg                  Power *et al.* 2009 \[[@B24-antibiotics-02-00115]\]
  Sorption to AS                           experimental                                 'negligible'                                                                               Batt *et al.* 2006 \[[@B25-antibiotics-02-00115]\]
  Sorption WWTP                            experimental                                 'negligible'                                                                               Göbel *et al.* 2007 \[[@B26-antibiotics-02-00115]\]
  Kd, AS                                   experimental                                 7.4; but strong adsorption in one soil                               L/kg                  Lin & Gan 2011 \[[@B16-antibiotics-02-00115]\]
  Kd, soil                                 experimental                                 26                                                                   L/kg                  Power *et al.* 2009 \[[@B24-antibiotics-02-00115]\]
  Kd, soil                                 experimental, soil *p*H 4.9                  9.7                                                                  L/kg                  Liu *et al.* 2010 \[[@B15-antibiotics-02-00115]\]
  Sorption to sludges                      experimental                                 ND in primary, secondary and digested sludge as well as in compost                         Martín *et al.* 2012 \[[@B27-antibiotics-02-00115]\]

antibiotics-02-00115-t002_Table 2

###### 

Biodegradability and elimination of TMP.

  Test Type                                                                     Inoculum                               Endpoint                               TMP Conc, mg/L                             Duration                                      Degradation                         Reference
  ----------------------------------------------------------------------------- -------------------------------------- -------------------------------------- ------------------------------------------ --------------------------------------------- ----------------------------------- ----------------------------------------------------------------
  Ready biodegradability OECD301F                                                                                      BOD/ThOD                               19.4                                                                                     0%                                  Halling-Sørensen *et al.* 2000 \[[@B18-antibiotics-02-00115]\]
  Ready biodegradability OECD 301D                                                                                     BOD/ThOD                               3.25 (TMP-naphtoate)                       28 day                                        4%                                  Alexy *et al.* 2004 \[[@B29-antibiotics-02-00115]\]
  Ready biodegradability OECD 301D, toxicity control/ cometabolic degradation                                          BOD/ThOD                               3.25 (TMP-naphtoate) plus sodium acetate   28 day                                        27%                                 Alexy *et al.* 2004 \[[@B29-antibiotics-02-00115]\]
  Degradation in a water/leaf system                                            fallen leaves, natural water           substance loss                         0.04                                       168 h                                         \~80%                               Bundschuh *et al.* 2009 \[[@B30-antibiotics-02-00115]\]
  Inherent respirometric test (Roche-internal)                                  mixed industrial-municipal AS          BOD/ThOD                               200                                        5 day                                         0%                                  Gröner 1981 \[[@B31-antibiotics-02-00115]\]
  Inherent biodegradability                                                                                            t½ primary degradation                 0.5                                        22--41 day                                                                        Halling-Sørensen *et al.* 2000 \[[@B18-antibiotics-02-00115]\]
  Inherent biodegradability (combined Zahn-Wellens/ CO2 evolution test)                                                DOC, BCO2                              100 mg TOC/l                               28 day                                        negative (toxic to sludge)          Gartiser *et al.* 2007 \[[@B21-antibiotics-02-00115]\]
  Inherent biodegradability                                                     nitrifying AS with long SRT (49 d)     substance loss                         0.25                                       96 h                                          \~70%                               Batt *et al.* 2006 \[[@B25-antibiotics-02-00115]\]
  Inherent biodegradability                                                     nitrifying AS with long SRT (49 d)     degradation half-life                  0.25                                       \~67 h                                                                            Batt *et al.* 2006 \[[@B25-antibiotics-02-00115]\]
  Inherent biodegradability OECD 303A                                           AS                                     substance loss                         0.03 radio-labelled                        21 day                                        \<1%                                Junker *et al.* 2006 \[[@B32-antibiotics-02-00115]\]
  Inherent biodegradability                                                     AS with 220 d SRT                      substance loss                         0.001                                                                                    74%                                 Yu *et al.* 2009 \[[@B33-antibiotics-02-00115]\]
  Inherent bio-degradability, small membrane bioreactor                         AS                                     primary degradation constant k~biol~                                                                                            0.22 ± 0.022 l × g~ss~^--1^d^--1^   Abegglen *et al.* 2009 \[[@B22-antibiotics-02-00115]\]
  (Inherent) Biodegradability                                                   primary sewage                         primary degradation                    0.02                                       54 day                                        \~40%, slow                         Pérez *et al.* 2005 \[[@B34-antibiotics-02-00115]\]
  (Inherent) Biodegradability                                                   AS                                     primary degradation                    0.02                                       54 day                                        NS/slight increase                  Pérez *et al.* 2005 \[[@B34-antibiotics-02-00115]\]
  (Inherent) Biodegradability                                                   nitrifying sludge                      primary degradation                    0.02                                       3 day                                         100%, rapid                         Pérez *et al.* 2005 \[[@B34-antibiotics-02-00115]\]
  Elimination                                                                   primary wastewater treatment                                                                                                                                           --13% to 31%                        Göbel *et al.* 2007 \[[@B26-antibiotics-02-00115]\]
  Elimination                                                                   conventional AS with 10--25 d SRT                                                                                                                                      --40 ± 20% to 20 ± 11%              Göbel *et al.* 2007 \[[@B26-antibiotics-02-00115]\]
  Elimination                                                                   AS with 60--80 d SRT                                                                                                                                                   87%--90%                            Göbel *et al.* 2007 \[[@B26-antibiotics-02-00115]\]
  Elimination                                                                   fixed-bed reactor                                                                                                                                                      12 ± 11% to 17 ± 11%                Göbel *et al.* 2007 \[[@B26-antibiotics-02-00115]\]
  Elimination                                                                   pilot membrane bioreactors in a WWTP   substance loss                         50 µg/L                                    SRT 15 day & HRT 9 h; SRT 30 day & HRT 13 h   86% SRT 15; 94% SRT 30              Schröder *et al.* \[[@B35-antibiotics-02-00115]\]
  Elimination                                                                   sand filter                                                                                                                                                            15%--74%                            Göbel *et al.* 2007 \[[@B26-antibiotics-02-00115]\]
  Elimination                                                                   sand filter                                                                                                                                                            60%                                 Göbel *et al.* 2005 \[[@B19-antibiotics-02-00115]\]

antibiotics-02-00115-t003_Table 3

###### 

Removal of TMP during sewage treatment.

  Sewage treatment plants (STP)   Type                                         Measurement                                                                           Removal                                Reference
  ------------------------------- -------------------------------------------- ---------------------------------------- -------------------------------------------- -------------------------------------- ----------------------------------------------------------------
  STPs Germany                    AS                                           substance loss, two analytical methods                                                18 ± 14%, 29 ± 17%                     Ternes *et al.* 1999 \[[@B42-antibiotics-02-00115]\]
  STPs Europe (n = 7)             AS                                           substance loss                                                                        0%, 4×\<10%, 30%, 40%                  Paxéus 2004 \[[@B43-antibiotics-02-00115]\]
  STPs Switzerland (n = 2)        AS                                           substance loss                                                                        74%                                    Göbel *et al.* 2005 \[[@B19-antibiotics-02-00115]\]
  STP Sweden                      AS                                           substance loss                                                                        49%                                    Bendz *et al.* 2005 \[[@B44-antibiotics-02-00115]\]
  STP Sweden (n = 2)              AS                                           substance loss                                                                        --550% (!) to 68%                      Lindberg *et al.* 2005 \[[@B45-antibiotics-02-00115]\]
  STP Sweden                      AS                                           substance loss                                                                        −45%, −1%, 40%                         Lindberg *et al.* 2006 \[[@B46-antibiotics-02-00115]\]
  STP France                      AS                                           substance loss                                                                        51%                                    Paffoni *et al.* 2006 \[[@B47-antibiotics-02-00115]\]
  STP Spain                       AS                                           substance loss                                                                        −128% to 71%                           Gros *et al.* 2007 \[[@B48-antibiotics-02-00115]\]
  STPs Croatia (n = 2)            AS                                           substance loss                                                                        −15%, 49%                              Senta *et al.* 2008 \[[@B49-antibiotics-02-00115]\]
  STPs Wales (n = 2)              AS                                           substance loss                                                                        47%, 70%                               Kasprzyk-Hordern *et al.* 2009 \[[@B50-antibiotics-02-00115]\]
  STP Spain (n = 2)               AS                                           substance loss                                                                        40.4 ± 25.4%                           Radjenovic *et al.* 2009 \[[@B23-antibiotics-02-00115]\]
  STPs Spain (n = 2)              membrane bioreactor                          substance loss                                                                        66.7 ± 20.6% 47.5 ± 22.5%              Radjenovic *et al.* 2009 \[[@B23-antibiotics-02-00115]\]
  STPs Canada (n = 2)             AS                                           substance loss                                                                        14 ± 2%, NS 38 ± 4%                    Segura *et al.* 2006 \[[@B51-antibiotics-02-00115]\]
  STP USA                         AS                                           substance loss                                                                        \~50%                                  Batt *et al.* 2006 \[[@B25-antibiotics-02-00115]\]
  STP USA                         AS                                           substance loss                                                                        69%                                    Brown *et al.* 2006 \[[@B52-antibiotics-02-00115]\]
  STP USA (n = 4)                 various                                      substance loss                                                                        50%, 61%, 66%, 67%, 69%, 83%           Karthikeyan & Meyer 2006 \[[@B53-antibiotics-02-00115]\]
  STP USA                         nitrifying AS                                substance loss                           influent \>0.01 µg/L (LOD), effluent \<LOD   not quantified                         Levine *et al.* 2006 \[[@B54-antibiotics-02-00115]\]
  STPs USA (n = 4)                AS                                           substance loss                                                                        70%, 76%, 82%, 97%                     Batt *et al.* 2007 \[[@B55-antibiotics-02-00115]\]
  STP Australia                   AS                                           substance loss                                                                        85%                                    Watkinson *et al.* 2007 \[[@B56-antibiotics-02-00115]\]
  STPs Japan (n = 4)              different secondary treatments               substance loss                                                                        −88%, −82%, −46%, 35%, 63%, 73%, 74%   Ghosh *et al.* 2009 \[[@B57-antibiotics-02-00115]\]
  STP China (n = 4)               different primary and secondary treatments   substance loss                                                                        −42%, −17%, −11%, 42%                  Gulkowska *et al.* 2008 \[[@B58-antibiotics-02-00115]\]
  STP Norway (n = 1)              AS                                           substance loss                                                                        --60% to 28%, values only from graph   Plósz *et al.* 2010 \[[@B59-antibiotics-02-00115]\]
  STP Sweden (n = 4)              AS                                           substance loss                                                                        4%, 13%, 63%, 76%; average 39%         Fick *et al.* 2011 \[[@B60-antibiotics-02-00115]\]
  STPs Ireland (n = 3)            AS                                           substance loss                                                                        0--94.6%                               Lacey *et al.* 2012 \[[@B61-antibiotics-02-00115]\]
  STPs Hong Kong/China (n = 7)    different secondary treatments               substance loss                                                                        43% overall removal                    Leung *et al.* 2012 \[[@B62-antibiotics-02-00115]\]
  STP Taiwan (n = 1)              primary, seconday & tertiary                 substance loss                                                                        \>99%                                  Lin *et al.* 2012 \[[@B63-antibiotics-02-00115]\]
  STPs Spain (n = 2)              AS                                           substance loss                                                                        8%, 29%                                Verlicchi *et al.* 2012 \[[@B64-antibiotics-02-00115]\]

antibiotics-02-00115-t004_Table 4

###### 

Environmental Fate of TMP.

  Endpoint                              Medium                                             Measurement                                       Conditions                                           Duration               Result                                                                                                 Reference
  ------------------------------------- -------------------------------------------------- ------------------------------------------------- ---------------------------------------------------- ---------------------- ------------------------------------------------------------------------------------------------------ -------------------------------------------------------------
  Hydrolysis                                                                                                                                                                                                             stable                                                                                                 Lam *et al.* 2004 \[[@B65-antibiotics-02-00115]\]
  Hydrolysis                                                                                                                                                                                                             stable                                                                                                 Michael *et al.* 2012 \[[@B66-antibiotics-02-00115]\]
  Aquatic photodegradation                                                                                                                                                                                               not readily photodegradable                                                                            Boxall *et al.* 2002 \[[@B67-antibiotics-02-00115]\]
  Aquatic photodegradation                                                                                                                                                                        42 day                 no photodegradation                                                                                    Boxall *et al.* 2004 \[[@B68-antibiotics-02-00115]\]
  Aquatic photodegradation              seawater, natural sunlight                                                                                                                                21 day                 stable                                                                                                 Lunestad *et al.* 1995 \[[@B69-antibiotics-02-00115]\]
  Aquatic photodegradation              Hg-Nd lamp, H~2~O~2~, tap water                                                                                                                           10 min; 20 min         \>90%; \>99%                                                                                           Türk 2007 \[[@B70-antibiotics-02-00115]\]
  Aquatic photodegradation                                                                                                                                                                                               \<10% UV only; up to 92% with UV, H~2~O~2~and scavengers                                               Rosario-Ortiz *et al.* 2010 \[[@B71-antibiotics-02-00115]\]
  Aquatic photodegradation              natural sunlight                                   substance loss                                    2 mg/L, *p*H 4,7&9                                   72 h                   slight degradation during daytime only, up to \~2% at 72 h                                             Wu *et al.* 2011 \[[@B72-antibiotics-02-00115]\]
  Aquatic photodegradation              natural sunlight                                   substance loss                                    2 mg/L, aluminium-wrapped dark control, *p*H 4,7&9   72 h                   increased degradation up to \~15% (*p*H 4 & 7) correlating with temperature                            Wu et al 2011 \[[@B72-antibiotics-02-00115]\]
  Aquatic photodegradation              natural sunlight                                   substance loss                                    10 mg/L demineralised water                          500 min                increased with Fenton reagent, decreased in simulated and natural wastewater                           Michael *et al.* 2012 \[[@B66-antibiotics-02-00115]\]
  Ozonation                                                                                                                                                                                                              rapid destruction                                                                                      Türk 2007 \[[@B70-antibiotics-02-00115]\]
  Environmental half-life               freshwater microcosm                               t½ measured                                                                                            5.7 ± 0.1 day                                                                                                                 Lam *et al.* 2004 \[[@B65-antibiotics-02-00115]\]
  Environmental half-life               freshwater                                         t½ estimate                                                                                            \>42 day                                                                                                                      Boxall *et al.* 2002 \[[@B67-antibiotics-02-00115]\]
  Environmental half-life               freshwater                                         t½ estimate                                                                                            20--100 day                                                                                                                   Zuccato *et al.* 2001 \[[@B73-antibiotics-02-00115]\]
  Environmentalhalf-life                marine sediment                                    t½ estimate                                                                                            \<60--100 day                                                                                                                 Boxall *et al.* 2002 \[[@B67-antibiotics-02-00115]\]
  Environmental half-life               marine sediment                                    t½ estimate                                                                                            75--100 ayd                                                                                                                   Hektoen *et al.* 1995 \[[@B74-antibiotics-02-00115]\]
  Elimination                           freshwater sediment                                primary degradation                                                                                    14 h                   15%                                                                                                    Löffler & Ternes 2003 \[[@B36-antibiotics-02-00115]\]
  Riverbank filtration                                                                     substance loss                                                                                                                \>75% removal                                                                                          Schmidt *et al.* 2006 \[[@B37-antibiotics-02-00115]\]
  Anaerobic biodegradability ISO11734                                                      methane production                                                                                                            NS                                                                                                     Gartiser *et al.* 2007 \[[@B21-antibiotics-02-00115]\]
  Anaerobic degradability               surplus sludge digestion                           primary degradation                                                                                                           \>99%                                                                                                  Göbel *et al.* 2005 \[[@B19-antibiotics-02-00115]\]
  Anaerobic biodegradability VDI 4630   manure & anaerobic bacteria                        primary degradation (LC/MS)                       2.8 mg/kg; 14 mg/kg                                  34 day                 98.9% day 8; 99.9% day 9                                                                               Mohring *et al.* 2009 \[[@B38-antibiotics-02-00115]\]
  Anaerobic degradation                 pig slurry                                                                                                                                                                       rapid degradation                                                                                      Grote *et al.* 2004 \[[@B39-antibiotics-02-00115]\]
  Sewater degradation                   seawater                                           DT50                                              0.001                                                \>100 day                                                                                                                     Benotti & Brownawell 2009 \[[@B41-antibiotics-02-00115]\]
  Soil degradation                      soil                                               DT50                                                                                                   110 day                                                                                                                       Boxall *et al.* 2005 \[[@B13-antibiotics-02-00115]\]
  Soil dissipation                      soil                                               DT50, DT90                                                                                             \<103 day, \>152 day                                                                                                          Boxall *et al.* 2006 \[[@B40-antibiotics-02-00115]\]
  Soil dissipation                      aerobic, non-sterile                               DT50                                              10 mg/kg                                             4 day                                                                                                                         Liu *et al.* 2010 \[[@B15-antibiotics-02-00115]\]
  Soil dissipation                      aerobic, sterile                                   DT50                                              10 mg/kg                                             64 day                                                                                                                        Liu *et al.* 2010 \[[@B15-antibiotics-02-00115]\]
  Soil dissipation                      anaerobic, non-sterile                             DT50                                              10 mg/kg                                             11 day                                                                                                                        Liu *et al.* 2010 \[[@B15-antibiotics-02-00115]\]
  Soil dissipation                      anaerobic, sterile                                 DT50                                              10 mg/kg                                             79 day                                                                                                                        Liu *et al.* 2010 \[[@B15-antibiotics-02-00115]\]
  Soil degradation                      aerobic soil                                       percentage of loss attributed to biodegradation   10 mg/kg                                             49 day                 \~28%                                                                                                  Liu *et al.* 2010 \[[@B15-antibiotics-02-00115]\]
  Soil degradation                      anaerobic soil                                     percentage of loss attributed to biodegradation   10 mg/kg                                             49 day                 \~56%                                                                                                  Liu *et al.* 2010 \[[@B15-antibiotics-02-00115]\]
  Soil degradation                      aerobic soil                                                                                         40 µg/kg dry weight                                  t½ = 26.1 day          *note:* no significant anaerobic degradation, no degradation in sterilised soil, nor in another soil   Lin & Gan 2011 \[[@B16-antibiotics-02-00115]\]
  Removal during soil passage           aerobic turfgrass soil, sampled at \~90 cm depth   substance loss during leaching                                                                                                91%--98%                                                                                               Bondarenko *et al.* 2012 \[[@B78-antibiotics-02-00115]\]

antibiotics-02-00115-t005_Table 5

###### 

Bioaccumulation data for TMP.

  Bioaccumulation                                                                        Organism                                Organ                         Dosage                                                              Duration                                                                    Result                                                                                                                             Reference
  -------------------------------------------------------------------------------------- --------------------------------------- ----------------------------- ------------------------------------------------------------------- --------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------
  Bioconcentration freshwater                                                            fish, trout                             autoradiographs               single oral dose                                                    up to 144 h                                                                 maximum concentrations given as DPMs only reached at 12--24 h (15 °C) respectively 48 h (7 °C), then rapid decline in both cases   Bergsjø *et al.* 1979 \[[@B80-antibiotics-02-00115]\]
  Bioconcentration freshwater                                                            fish, trout                             liver, muscle, plasma                                                                             84 h                                                                        \~0.16; \~0.04; \~0.01                                                                                                             Bergsjø & Søgnen 1980 \[[@B9-antibiotics-02-00115]\]
  Bioconcentration marine                                                                fish, trout                             liver, muscle, plasma,                                                                            84 h                                                                        \~0.2--0.32; \~0.08--0.12; \~0.03--0.07                                                                                            Bergsjø & Søgnen 1980 \[[@B9-antibiotics-02-00115]\]
  Bioconcentration aquatic                                                               physico-chemical activity-modelled                                                                                                                                                                                    higher predicted TMP concentration in biota at *p*H 6 than at *p*H 9 due to increase in sediment concentration at *p*H 9           Trapp *et al.* 2010 \[[@B28-antibiotics-02-00115]\]
  Depuration marine                                                                      fish, Japanese seabass                  muscle, blood,liver, kidney   5 oral doses, one per day, of 125 mg sulfamethazine and 25 mg TMP   minimum holding period after last dose 26 days at 22 °C, 30 days at 16 °C                                                                                                                                      Fang *et al.* 2003 \[[@B81-antibiotics-02-00115]\]
  Biomonitoring freshwater USA: 5 wastewater-influenced rivers, 1 pristine control       fish (various local species)            muscle, liver                 not measured                                                        permanent (wild fish)                                                       ND (\<2.2); ND (\<8.0) LODs in ng/g                                                                                                Ramirez *et al.* 2009 \[[@B82-antibiotics-02-00115]\]
  Biomonitoring freshwater Sweden: 4 wastewater-influenced rivers, 2 pristine controls   fish, perch                             muscle                                                                                            permanent (wild fish)                                                       ND (\<0.1 ng/g LOQ)                                                                                                                Fick *et al.* 2011 \[[@B60-antibiotics-02-00115]\]
  Bioaccumulation plants                                                                 lettuce and carrots *(Daucus carota)*   lettuce leaf, carrot root     1 mg/kg soil dry weight                                             103 days lettuce, 152 days carrots                                          soil-based uptake factor lettuce 0.06, carrot 0.08; porewater-based uptake factor lettuce 0.68, carrot 0.86                        Boxall *et al.* 2006 \[[@B40-antibiotics-02-00115]\]
  Bioaccumulation plants                                                                 2 cabbage cultivars                     leaf/stem root                232.5 µg/L hydroponic nutrient solution                             51 days                                                                     bioaccumulation factor 0.0383--0.3074 (wet weight), 0.0451--7.037 (dry weight)                                                     Herklotz *et al.* 2010 \[[@B83-antibiotics-02-00115]\]
  Bioaccumulation plants                                                                 sweet maize, carrot, tomato, potato                                   field fertilised with dehydrated sewage sludge (biosolids)                                                                                      equivocal/ NS                                                                                                                      Sabourin *et al.* 2012 \[[@B84-antibiotics-02-00115]\]

HRT = Hydraulic retention time; LOD = limit of detection; ND = not detected; NS = not significant; SRT = sludge retention time.

antibiotics-02-00115-t006_Table 6

###### 

Micro-organism and activated-sludge toxicity data.

  Organism/Sludge                                          Systematic Group                  Endpoint                                                                                                                   Duration                                                  Value, mg/L                   Reference
  -------------------------------------------------------- --------------------------------- -------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------- ----------------------------- ----------------------------------------------------------------
  AS, OECD209                                                                                EC50                                                                                                                                                                                 17.8                          Halling-Sørensen *et al.* 2000 \[[@B18-antibiotics-02-00115]\]
  AS, OECD209                                                                                EC50; EC20                                                                                                                 3 h                                                       \>200; 19                     Oggier/BMG 2011, GLP \[[@B128-antibiotics-02-00115]\]
  Anaerobic sludge inhibition ISO13641                                                       EC50                                                                                                                       7 days                                                    \>100                         Gartiser *et al.* 2007 \[[@B21-antibiotics-02-00115]\]
  *Vibrio fischeri*                                        bacteria, marine                  IC50                                                                                                                       15 min                                                    183.3                         Blaise *et al.* 2006 \[[@B129-antibiotics-02-00115]\]
  *Vibrio fischeri* ISO 11348--3                           bacteria, marine                  IC50                                                                                                                       15 min                                                    176.7                         Kim *et al.* 2007 \[[@B130-antibiotics-02-00115]\]
  *Vibrio fischeri*                                        bacteria, marine                  IC50                                                                                                                       30 min                                                    23.3                          Isidori *et al.* 2005 \[[@B131-antibiotics-02-00115]\]
  Human nanobacteria                                       bacteria                          MIC                                                                                                                        14 days                                                   3.9                           Ciftcioglu *et al.* 2002 \[[@B132-antibiotics-02-00115]\]
  AS, OECD209                                              bacteria                          NOEC; EC10                                                                                                                 3 h                                                       100; 0.435                    Oggier/BMG 2011, GLP \[[@B128-antibiotics-02-00115]\]
  AS in Closed Bottle ready biodegradation test OECD301D   bacteria                          NOEC toxicity control                                                                                                                                                                3.25 mg/L TMP-naphthoate      Alexy *et al.* 2004 \[[@B29-antibiotics-02-00115]\]
  AS in Closed Bottle ready biodegradation test OECD301D   bacteria                          LOEC colony-forming units                                                                                                                                                            4.6 µg/L TMP-naphthoate       Alexy *et al.* 2004 \[[@B29-antibiotics-02-00115]\]
  *Pantoea agglomerans*                                    soil bacterium                    NOEC                                                                                                                                                                                 0.02                          Tappe *et al.* 2006 \[[@B133-antibiotics-02-00115]\]
  Nitrification inhibition test                            nitrifying bacteria               NOEC                                                                                                                                                                                 0.05                          Ghosh *et al.* 2009 \[[@B57-antibiotics-02-00115]\]
  Nitrification inhibition test                            nitrifying bacteria               NOEC; EC10                                                                                                                                                                           96; \>96                      Oggier/BMG 2011, GLP \[[@B134-antibiotics-02-00115]\]
  Fungal growth on fallen leaves                           fungi                             LOEC; NOEC                                                                                                                 TMP together with 4 other antibiotics, all at same conc   40 µg/L; 0.4 µg/L             Bundschuh *et al.* 2009 \[[@B30-antibiotics-02-00115]\]
  Natural soil respiration                                 all aerobic soil microorganisms   EC10 (0--4 days)                                                                                                                                                                     20 mg/kg soil (dry weight)    Liu *et al.* 2009 \[[@B135-antibiotics-02-00115]\]
  Natural soil respiration                                 all aerobic soil microorganisms   after 4 days consistent increase in respiration *vs.* controls in all concentrations up to the highest of 300 mg/kg soil                                                             300 mg/kg soil (dry weight)   Liu *et al.* 2009 \[[@B135-antibiotics-02-00115]\]
  Natural soil                                             bacteria (colony-forming units)   NOEC/LOEC                                                                                                                                                                            10 mg/kg                      Liu *et al.* 2010 \[[@B15-antibiotics-02-00115]\]

antibiotics-02-00115-t007_Table 7

###### 

Acute ecotoxicity data for TMP.

  Organism                                                         Systematic Group       Endpoint            Duration   Value, mg/L                                                 Reference
  ---------------------------------------------------------------- ---------------------- ------------------- ---------- ----------------------------------------------------------- ----------------------------------------------------------------
  *Anabaena cylindrica*                                            Cyanobacteria          EC50                6 days     ***\>200***                                                 Ando *et al.* 2007 \[[@B136-antibiotics-02-00115]\]
  *Anabaena flos-aquae*                                            Cyanobacteria          EC50                6 days     ***\>200***                                                 Ando *et al.* 2007 \[[@B136-antibiotics-02-00115]\]
  *Anabaena variabilis*                                            Cyanobacteria          EC50                6 days     ***11***                                                    Ando *et al.* 2007 \[[@B136-antibiotics-02-00115]\]
  *Microcystis aeruginosa*                                         Cyanobacteria          EC50                7 days     112                                                         Holten Lützhøft *et al.* 1999 \[[@B138-antibiotics-02-00115]\]
  *M. aeruginosa*                                                  Cyanobacteria          EC50                6 days     150                                                         Ando *et al.* 2007 \[[@B136-antibiotics-02-00115]\]
  *M. aeruginosa*                                                  Cyanobacteria          EC50                           ***129.6***                                                 ***geometrical average***
  *Microcystis wesenbergii*                                        Cyanobacteria          EC50                6 days     ***\>200***                                                 Ando *et al.* 2007 \[[@B136-antibiotics-02-00115]\]
  *Nostoc* sp. PCC7120                                             Cyanobacteria          EC50                6 days     ***53***                                                    Ando *et al.* 2007 \[[@B136-antibiotics-02-00115]\]
  *Synechococcus leopoldensis*                                     Cyanobacteria          EC50                6 days     ***\>200***                                                 Ando *et al.* 2007 \[[@B136-antibiotics-02-00115]\]
  *Synechococcus* sp. PCC7002                                      Cyanobacteria          EC50                6 days     ***\>200***                                                 Ando *et al.* 2007 \[[@B136-antibiotics-02-00115]\]
  *Rhodomonas salina* ISO 8692                                     Algae, marine          EC50                72 h       ***16***                                                    Holten Lützhøft *et al.* 1999 \[[@B138-antibiotics-02-00115]\]
  *Phaeodactylum tricornutum*                                      Algae, marine          EC50                72 h       ***5.1***                                                   Claessens *et al.* 2009 \[[@B137-antibiotics-02-00115]\]
  *Pseudokirchneriella subcapitata (=Selenastrum capricornutum)*   Algae                  EC50                72 h       40                                                          Yang *et al.* 2008 \[[@B139-antibiotics-02-00115]\]
  *P. subcapitata*                                                 Algae                  EC50                72 h       80.3                                                        Eguchi *et al.* 2004 \[[@B140-antibiotics-02-00115]\]
  *P. subcapitata*                                                 Algae                  EC50                72 h       96.7                                                        Blaise *et al.* 2006 \[[@B129-antibiotics-02-00115]\]
  *P. subcapitata* OECD 201                                        Algae                  ErC50               72 h       98                                                          Bogers 1996a GLP \[[@B141-antibiotics-02-00115]\]
  *P. subcapitata* ISO 8692                                        Algae                  EC50                72 h       110                                                         Halling-Sørensen *et al.* 2000 \[[@B18-antibiotics-02-00115]\]
  *P. subcapitata*                                                 Algae                  EC50                72 h       130                                                         Holten Lützhøft *et al.* 1999 \[[@B138-antibiotics-02-00115]\]
  *P. subcapitata*                                                 Algae                  EC50                72 h       ***87.1***                                                  ***geometrical average***
  *Lemna gibba*                                                    Angiospermae           EC50                7 days     \>1 HTC                                                     Brain *et al.* 2004 \[[@B142-antibiotics-02-00115]\]
  *Lemna minor* OECD 221                                           Angiospermae           ErC50               7 days     ***215***                                                   this work, GLP, Oggier 2011 \[[@B143-antibiotics-02-00115]\]
  *Hydra attenuata*                                                Cnidaria               EC50                96 h       \>85.3                                                      Blaise *et al.* 2006 \[[@B129-antibiotics-02-00115]\]
  *H. attenuata*                                                   Cnidaria               EC50                96 h       \>100                                                       Quinn *et al.* 2008a \[[@B144-antibiotics-02-00115]\]
  *H. attenuata*                                                   Cnidaria               EC50                96 h       ***\>92.4***                                                ***geometrical average***
  *Brachionus koreanus*                                            Rotatoria (brackish)   EC50                24 h       198.5                                                       Rhee *et al.* 2012 \[[@B145-antibiotics-02-00115]\]
  *Daphnia magna*                                                  Crustacea              EC50                48 h       92                                                          Park & Choi 2008 \[[@B146-antibiotics-02-00115]\]
  *D. magna* OECD 202                                              Crustacea              EC50                48 h       \>100 HTC                                                   Bogers 1996b GLP \[[@B147-antibiotics-02-00115]\]
  *D. magna* US EPA 600/4_90/027                                   Crustacea              EC50                48 h       123                                                         Halling-Sørensen *et al.* 2000 \[[@B18-antibiotics-02-00115]\]
  *D. magna*                                                       Crustacea              EC50                48 h       149                                                         De Liguoro *et al.* 2009 \[[@B148-antibiotics-02-00115]\]
  *D. magna*                                                       Crustacea              EC50                48 h       167.4                                                       Kim *et al.* 2007 \[[@B130-antibiotics-02-00115]\]
  *D. magna*                                                       Crustacea              EC50                96 h       296                                                         Iannacone & Alvariño 2009 \[[@B149-antibiotics-02-00115]\]
  *D. magna*                                                       Crustacea              EC50                48 h       ***142.4***                                                 ***geometrical average***
  *Moina macrocopa*                                                Crustacea              EC50                48 h       ***54.8***                                                  Choi *et al.* 2008 \[[@B150-antibiotics-02-00115]\]
  *Thamnocephalus platyurus*                                       Crustacea              EC50                24 h       ***161.2***                                                 Blaise *et al.* 2006 \[[@B129-antibiotics-02-00115]\]
  *Crassostrea gigas*                                              Mollusca, marine       EC50 embryolarval   24 h       ***\~31.6***√(10×100)                                       Claessens *et al.* 2009 \[[@B137-antibiotics-02-00115]\]
  *Danio rerio* OECD 203                                           Fish                   NOEC                72 h       100                                                         Halling-Sørensen *et al.* 2000 \[[@B18-antibiotics-02-00115]\]
  *D. rerio*                                                       Fish                   NOEC                96 h       100                                                         Blaise *et al.* 2006 \[[@B129-antibiotics-02-00115]\]
  *D. rerio*                                                       Fish                   LC50                96 h       ***\>100***                                                 ***geometrical average***
  *Oryzias latipes*                                                Fish                   LC50                96 h       ***\>100***                                                 Kim *et al.* 2007 \[[@B130-antibiotics-02-00115]\]
  *Oncorhynchus mykiss*                                            Fish                   LC50                84 h       **\>75**HTC                                                 Bergsjø & Søgnen 1980 \[[@B9-antibiotics-02-00115]\]
  *O. mykiss*                                                      Fish                   LC50                96 h       \(3\) *note:* miscitation, not a concentration but a dose   miscited in Kolpin *et al.* \[[@B124-antibiotics-02-00115]\]

*Note:* In case of several values for the same species, the geometrical average was calculated \[[@B155-antibiotics-02-00115]\]. Values in ***bold italics*** are the values used for PNEC derivation while the single value in brackets was not used for the PNEC, see text. HTC = Highest tested concentration.

antibiotics-02-00115-t008_Table 8

###### 

Chronic Ecotoxicity Data for TMP.

  Organism                                                         Systematic Group       Endpoint    Duration   Value, mg/L             Reference
  ---------------------------------------------------------------- ---------------------- ----------- ---------- ----------------------- ---------------------------------------------------------------------------
  *Anabaena cylindrica*                                            Cyanobacteria          NOEC        6 days     ***≥200***              Ando *et al.* 2007 \[[@B136-antibiotics-02-00115]\]
  *Anabaena flos-aquae*                                            Cyanobacteria          NOEC        6 days     ***≥200***              Ando *et al.* 2007 \[[@B136-antibiotics-02-00115]\]
  *Anabaena variabilis*                                            Cyanobacteria          NOEC        6 days     ***3.1***               Ando *et al.* 2007 \[[@B136-antibiotics-02-00115]\]
  *Microcystis aeruginosa*                                         Cyanobacteria          NOEC        6 days     ***100***               Ando *et al.* 2007 \[[@B136-antibiotics-02-00115]\]
  *Microcystis wesenbergii*                                        Cyanobacteria          NOEC        6 days     ***3.1***               Ando *et al.* 2007 \[[@B136-antibiotics-02-00115]\]
  *Nostoc* sp. PCC7120                                             Cyanobacteria          NOEC        6 days     ***3.1***               Ando *et al.* 2007 \[[@B136-antibiotics-02-00115]\]
  *Synechococcus leopoldensis*                                     Cyanobacteria          NOEC        6 days     ***13***                Ando *et al.* 2007 \[[@B136-antibiotics-02-00115]\]
  *Synechococcus* sp. PCC7002                                      Cyanobacteria          NOEC        6 days     ***50***                Ando *et al.* 2007 \[[@B136-antibiotics-02-00115]\]
  *Phaeodactylum tricornutum*                                      Diatom Algae, marine   NOEC        72 h       ***2.4***               Claessens *et al.* 2009 \[[@B137-antibiotics-02-00115]\]
  *Pseudokirchneriella subcapitata (=Selenastrum capricornutum)*   Green Algae            NOEC        72 h       16                      Yang *et al.* 2008 \[[@B139-antibiotics-02-00115]\]
  *P. subcapitata*                                                 Green Algae            NOEC        72 h       25.5                    Eguchi *et al.* 2004 \[[@B140-antibiotics-02-00115]\]
  *P. subcapitata*                                                 Green Algae            NOEC        72 h       32                      Bogers/NOTOX 1996a GLP \[[@B141-antibiotics-02-00115]\]
  *P. subcapitata*                                                 Green Algae            NOEC        72 h       ***23.5***              *geometrical average*
  *Lemna gibba*                                                    Angiospermae           NOEC        7 days     (\>1 HTC) not used\*    Brain *et al.* 2004 \[[@B142-antibiotics-02-00115]\]
  *Lemna minor*                                                    Angiospermae           NOEC        7 days     ***53.5***              this work, GLP Oggier 2001 \[[@B143-antibiotics-02-00115]\]
  *Hydra attenuata*                                                Cnidaria               NOEC        96 h       \>100                   Quinn *et al.* 2008a \[[@B144-antibiotics-02-00115]\]
  *H. attenuata*                                                   Cnidaria               NOEC        96 h       25                      Quinn *et al.* 2008b \[[@B151-antibiotics-02-00115]\]
  *H. attenuata*                                                   Cnidaria               NOEC        96 h       ***\>50***              ***geometrical average***
  *Brachionus koreanus*                                            Rotatoria (brackish)   NOEC/LOEC   10 days    (0.01/0.1) not used\*   Rhee *et al.* 2012 \[[@B145-antibiotics-02-00115]\]
  *Daphnia magna*                                                  Crustacea              NOEC        21 days    ***6***                 Park & Choi 2008 \[[@B146-antibiotics-02-00115]\]
  *Daphnia magna*                                                  Crustacea              NOEC        6 days     (0.01) not used\*       Flaherty & Dodson 2005 \[[@B152-antibiotics-02-00115]\]
  *Moina macrocopa*                                                Crustacea              NOEC        21 days    ***≥30*** HTC           Park & Choi 2008 \[[@B146-antibiotics-02-00115]\]
  *Danio rerio*                                                    Fish                   NOEC        35 days    ***100***HTC            this work, GLP, Gilberg & Hamberger 2011 \[[@B153-antibiotics-02-00115]\]
  *Xenopus laevis*                                                 Amphibia               EC10        96 h       ***≥100***              Richards & Cole 2006 \[[@B154-antibiotics-02-00115]\]

Note: In case of several values for the same species, the geometrical average was calculated. Values in ***bold italics*** are the values used for PNEC derivation. HTC = Highest tested concentration. Endpoints/ values in brackets were not used. \* = See text.
